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Background: The VEDERA (Very Early vs. Delayed Etanercept in Rheumatoid Arthritis) randomised
controlled trial compared the effect of conventional synthetic disease-modifying anti-rheumatic drug
(csDMARD) therapy with biologic DMARD (bDMARD) therapy using the tumour necrosis factor inhibitor
etanercept in treatment-naive, early rheumatoid arthritis patients. The CADERA (Coronary Artery Disease
Evaluation in Rheumatoid Arthritis) trial was a bolt-on study in which VEDERA patients underwent
cardiovascular magnetic resonance imaging to detect preclinical cardiovascular disease at baseline and
following treatment.
Objectives: To evaluate whether or not patients with treatment-naive early rheumatoid arthritis have
evidence of cardiovascular disease compared with matched control subjects; whether or not this is
modifiable with DMARD therapy; and whether or not bDMARDs confer advantages over csDMARDs.
Design: The VEDERA patients underwent cardiovascular magnetic resonance imaging at baseline and at
1 and 2 years after treatment.
Setting: The setting was a tertiary centre rheumatology outpatient clinic and specialist cardiovascular
magnetic resonance imaging unit.
Participants: Eighty-one patients completed all assessments at baseline, 71 completed all assessments
at 1 year and 56 completed all assessments at 2 years. Patients had no history of cardiovascular disease,
had had rheumatoid arthritis symptoms for ≤ 1 year, were DMARD treatment-naive and had a minimum
Disease Activity Score-28 of 3.2. Thirty control subjects without cardiovascular disease were approximately
individually matched by age and sex to the first 30 CADERA patients. Patients with a Disease Activity
Score-28 of ≥ 2.6 at 48 weeks were considered non-responders.
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Interventions: In the VEDERA trial patients were randomised to group 1, immediate etanercept and
methotrexate, or group 2, methotrexate± additional csDMARD therapy in a treat-to-target approach, with a
switch to delayed etanercept and methotrexate in the event of failure to achieve clinical remission at 6 months.
Main outcome measures: The primary outcome measure was difference in baseline aortic distensibility
between control subjects and the early rheumatoid arthritis group and the baseline to year 1 change in
aortic distensibility in the early rheumatoid arthritis group. Secondary outcome measures were myocardial
perfusion reserve, left ventricular strain and twist, left ventricular ejection fraction and left ventricular mass.
Results: Baseline aortic distensibility [geometric mean (95% confidence interval)] was significantly reduced
in patients (n = 81) compared with control subjects (n = 30) [3.0 × 10–3/mmHg (2.7 × 10–3/mmHg to
3.3 × 10–3/mmHg) vs. 4.4 × 10–3/mmHg (3.7 × 10–3/mmHg to 5.2 × 10–3/mmHg), respectively; p < 0.001].
Aortic distensibility [geometric mean (95% confidence interval)] improved significantly from baseline to
year 1 across the whole patient cohort (n = 81, with imputation for missing values) [3.0 × 10–3/mmHg
(2.7 × 10–3/mmHg to 3.4 × 10–3/mmHg) vs. 3.6 × 10–3/mmHg (3.1 × 10–3/mmHg to 4.1 × 10–3/mmHg),
respectively; p < 0.001]. No significant difference in aortic distensibility improvement between baseline
and year 1 was seen in the following comparisons (geometric means): group 1 (n = 40 at baseline) versus
group 2 (n = 41 at baseline): 3.8 × 10–3/mmHg versus 3.4 × 10–3/mmHg, p = 0.49; combined groups 1
and 2 non-responders (n = 38) versus combined groups 1 and 2 responders (n = 43): 3.5 × 10–3/mmHg
versus 3.6 × 10–3/mmHg, p = 0.87; group 1 non-responders (n = 17) versus group 1 responders (n = 23):
3.6 × 10–3/mmHg versus 3.9 × 10–3/mmHg, p = 0.73. There was a trend towards a 10–30% difference in
aortic distensibility between (group 1) responders who received first-line etanercept (n = 23) and (group 2)
responders who never received etanercept (n = 13): 3.9 × 10–3/mmHg versus 2.8 × 10–3/mmHg, p = 0.19;
ratio 0.7 (95% confidence interval 0.4 to 1.2), p = 0.19; ratio adjusted for baseline aortic distensibility
0.8 (95% confidence interval 0.5 to 1.2), p = 0.29; ratio fully adjusted for baseline characteristics 0.9
(95% confidence interval 0.6 to 1.4), p = 0.56.
Conclusions: The CADERA establishes evidence of the vascular changes in early rheumatoid arthritis
compared with controls and shows improvement of vascular changes with rheumatoid arthritis DMARD
therapy. Response to rheumatoid arthritis therapy does not add further to modification of cardiovascular
disease but, within the response to either strategy, etanercept/methotrexate may confer greater benefits
over standard methotrexate/csDMARD therapy.
Trial registration: Current Controlled Trials ISRCTN89222125 and ClinicalTrials.gov NCT01295151.
Funding: This project was funded by the Efficacy and Mechanism Evaluation programme, a Medical
Research Council and National Institute for Health Research (NIHR) partnership, and will be published in
full in Efficacy and Mechanism Evaluation; Vol. 8, No. 4. See the NIHR Journals Library website for further
project information. Pfizer Inc. (New York, NY, USA) supported the parent study, VEDERA, through an
investigator-sponsored research grant reference WS1092499.
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Rheumatoid arthritis is mainly known for the disabling joint changes that it causes, such as stiffness andpain. Patients with rheumatoid arthritis also have a higher rate of heart and blood vessel abnormalities,
including a higher risk of heart attack and stroke, than the general population. This is thought to be
caused by widespread inflammation affecting not only the joints but also the heart and blood vessels.
Newer treatments for rheumatoid arthritis work well to control inflammation in the joints. The aim of the
CADERA (Coronary Artery Disease Evaluation in Rheumatoid Arthritis) study was to find out whether or
not these treatments also improve the health of the blood vessels.
The CADERA study was carried out alongside a larger, randomised study in which patients with newly
diagnosed rheumatoid arthritis received either standard treatment or more effective anti-inflammatory
treatment called ‘biologics’, which directly target the substances that cause inflammation.
Eighty-one patients with newly diagnosed rheumatoid arthritis were randomly started on standard
treatment or biologics. At 1 and 2 years after treatment was started, magnetic resonance imaging was
used to provide detailed images that can be used to detect the presence and extent of heart and blood
vessel problems.
We found that, before any treatment, rheumatoid arthritis patients showed changes of blood vessel
function compared with a group of 30 control subjects without rheumatoid arthritis of similar age and sex.
Both types of rheumatoid arthritis treatment improved blood vessel function but there was no significant
benefit of the newer biologic treatment compared with the standard treatment, although small differences
were seen.
The results show that rheumatoid arthritis patients, even at an early stage of their disease, have changes
in blood vessel function and that this can be improved with rheumatoid arthritis treatment. Whether or
not these improvements lead to lower rates of heart attacks and strokes needs to be established in
future studies.
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Rheumatoid arthritis is a chronic, systemic, inflammatory arthritis affecting over 400,000 (0.8%) of the UK
population. Rheumatoid arthritis has considerable health and socioeconomic impacts. The life expectancy
of patients with rheumatoid arthritis is reduced and the mortality rate is increased up to threefold compared
with the general population. This is largely because of the increased frequency of premature cardiovascular
disease, which accounts for up to 40% of mortality in rheumatoid arthritis patients and is independent of and
incremental to traditional cardiovascular disease risk factors.
According to current guidelines, patients with newly diagnosed rheumatoid arthritis should be treated with
conventional synthetic disease-modifying anti-rheumatic drug (csDMARD) therapy in combination with
short-term glucocorticoids in a 'treat-to-target' (with the target of remission) approach. Biologic disease-
modifying anti-rheumatic drug (bDMARD) therapy, including tumour necrosis factor inhibitor therapy, is
recommended in patients with inadequate disease control with csDMARDs [in the UK, National Institute
for Health and Care Excellence guidelines permit bDMARD after failure of at least after two conventional
agents, including methotrexate and in the presence of high disease activity].
Treatment of rheumatoid arthritis with methotrexate and tumour necrosis factor inhibitors has been shown
to have beneficial effects on cardiovascular disease in epidemiological studies, with relative risks in the range
of 0.72 and 0.46–0.70, respectively, in patients with established rheumatoid arthritis. It is not clearly known
if patients with a new diagnosis of very early rheumatoid arthritis already have signs of cardiovascular
disease, if disease-modifying anti-rheumatic drug (DMARD) therapy confers benefits in this patient group
and if DMARD therapy reduces the incidence of cardiovascular disease, including whether or not bDMARD
therapy has additional benefits over csDMARDs.
The VEDERA (Very Early vs. Delayed Etanercept in early Rheumatoid Arthritis) study was a phase IV, pragmatic,
single-centre, open-label randomised controlled trial with the aim of determining the effect of bDMARD therapy
with tumour necrosis factor inhibitor in patients with new-onset, treatment-naive early rheumatoid arthritis
compared with standard methotrexate± additional csDMARD therapy in a treat-to-target approach (with
escalation to tumour necrosis factor inhibitor if clinical remission was not achieved). Participants were randomised
to one of two first-line therapeutic strategies: (1) group 1 – immediate tumour necrosis factor inhibitor
(etanercept) and methotrexate or (2) group 2: methotrexate± additional csDMARD therapy in a treat-to-target
approach, with switch to delayed etanercept and methotrexate in the event of failure to achieve clinical remission
at 6 months. The primary end point of the VEDERA trial was a comparison of the proportion of patients in each
treatment arm achieving Disease Activity Score-28 remission at 1 year. Secondary end points included evaluation
of the response to first-line etanercept compared with delayed etanercept (following methotrexate).
The CADERA (Coronary Artery Disease Evaluation in Rheumatoid Arthritis) study was a bolt-on study to the
VEDERA trial in which patients randomised in the VEDERA trial underwent additional multiparametric
cardiovascular magnetic resonance imaging to assess cardiovascular disease at baseline and after initiation
of either of the two treatment strategies.
Objectives
Primary objectives
l To determine if cardiovascular abnormalities, as assessed by cardiovascular magnetic resonance
imaging, are present in a treatment-naive inception cohort of early rheumatoid arthritis patients
compared with control subjects.
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l To establish whether or not (any) rheumatoid arthritis DMARD strategy is associated with improvement in
cardiovascular abnormalities, as measured by cardiovascular magnetic resonance imaging, in a treatment-
naive inception cohort of early rheumatoid arthritis patients over a 1-year period.
l To establish whether or not tumour necrosis factor inhibitor therapy confers a quantitative difference in
cardiovascular disease, as measured by cardiovascular magnetic resonance imaging, compared with standard
therapy in a treatment-naive inception cohort of early rheumatoid arthritis patients over a 1-year period.
Secondary objectives
l To determine cardiovascular changes, as assessed by cardiovascular magnetic resonance imaging, in a
treatment-naive inception cohort of early rheumatoid arthritis patients over a 2-year period.
l In additional analysis (in line with the VEDERA parent study), following a protocol amendment, to
evaluate the response relative to Disease Activity Score-28 control (Disease Activity Score-28 category
of remission-defined clinical response/non-response status) and therapeutic intervention (tumour
necrosis factor inhibitor/methotrexate and csDMARD including methotrexate).
Methods
Design
The CADERA study was a bolt-on study to the VEDERA parent randomised controlled trial. Patients
recruited to the VEDERA trial and randomised to the csDMARD or bDMARD treatment group underwent
cardiovascular resonance imaging at baseline and at 1 year and 2 years following initiation of therapy.
Setting
Participants were recruited from a single tertiary centre, an early rheumatoid arthritis rheumatology outpatient
clinic (Chapel Allerton Hospital, Leeds, UK), and underwent cardiovascular magnetic resonance imaging at
the Multidisciplinary Cardiovascular Research Centre (MCRC) at the Leeds Institute of Cardiovascular and
Metabolic Medicine.
Participants
The methods used in the VEDERA and CADERA studies have been published previously. Patients were
recruited between February 2012 and November 2015. Consecutive patients diagnosed with new-onset
rheumatoid arthritis according to American College of Rheumatology/European League Against Rheumatism
2010 criteria were invited to enrol into the VEDERA randomised controlled trial and parallel CADERA
substudy. Thirty control subjects (free of cardiovascular disease) were recruited through advertisements,
e-mail and word of mouth and were approximately individually matched by age and sex to the first 30
CADERA patients.
Outcome measures
The primary outcome measure was difference in aortic distensibility between patients and control subjects
at baseline and in patients from baseline to 1 year of follow-up.
Secondary outcome measures were myocardial perfusion reserve, left ventricular strain and twist, left
ventricular ejection fraction and left ventricular mass.
The exploratory outcome measure was myocardial extracellular volume.
Sample size
The sample size estimation for the primary end point aortic distensibility was based on previous published
studies showing improved aortic distensibilty in rheumatoid arthritis patients in response to interleukin-1-
directed therapy. Thirty-three patients in each treatment group would equate to 80% power to detect a
difference in aortic distensibility between the two treatment groups at a 5% significance level.
SCIENTIFIC SUMMARY
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Interventions
All recruited patients were randomised into two groups according to the VEDERA protocol.
1. Group 1: experimental treatment arm – etanercept group: immediate etanercept and methotrexate treatment.
2. Group 2: control treatment arm – standard treatment group: initial myocardial extracellular volume
monotherapy with treat-to-target regimen; escalation to combination DMARD therapy at or after 8 weeks
(up to week 24) if failing to meet the predefined target at 4-weekly assessments, and if failing to meet
the predefined target of clinical remission at week 24, step up to bDMARD, etanerceptand methotrexate.
Etanercept (Enbrel®, Pfizer Inc. New York, NY, USA) is a human tumour necrosis factor receptor p75Fc
fusion protein produced by recombinant deoxyribonucleic acid (DNA) technology. Methotrexate and/or
additional csDMARDs include sulfasalazine and hydroxychloroquine.
Study procedures
All patients underwent screening within the 4 weeks prior to the baseline visit for the VEDERA trial. At the
baseline visit eligibility for the study was confirmed, patients were randomised to one of the treatment
groups and study treatment was initiated. Further visits, which included assessment of disease activity,
took place at weeks 4, 12 and every 12 weeks thereafter, up to week 96, for both treatment arms, with
additional visits (for group 2) at week 8, 16 and 20 for safety and efficacy within a treat-to-target protocol.
At baseline and at 1 and 2 years following initiation of therapy, patients recruited to the CADERA study
were invited for cardiovascular magnetic resonance imaging. The cardiovascular magnetic resonance
imaging protocol included aortic cine imaging, cine imaging in left ventricular short- and long-axis
orientations, myocardial tissue tagging, adenosine stress and rest first-pass perfusion imaging using a
dual-bolus technique, with intravenous infusion of 0.01 and 0.1 mmol/kg gadopentetate dimeglumine
(Magnevist®, Bayer, Berlin, Germany), myocardial T1 mapping pre and post contrast and late gadolinium
enhancement imaging.
Analysis
All post-processing analysis of cardiovascular magnetic resonance scans was performed by experienced
blinded assessors using CVI 42 software (Circle Cardiovascular Imaging, Calgary, Canada). Aortic
distensibility was calculated from aortic cine images according to previously described methods. Left
ventricular contours were drawn manually at both end-diastole and end-systole on the left ventricular
short-axis cine stack and left ventricular volumes and mass derived. Left ventricular strain and peak left
ventricular twist were derived from tissue tagging images and myocardial extracellular volume was derived
from pre- and post-contrast T1 mapping.
Patients were compared with control subjects for the primary outcome, aortic distensibility, using matched
pairs analysis and regression analysis. The objective was to determine if a significant difference (p < 0.05)
existed between patients and control subjects and to estimate the magnitude of this difference as a
95% confidence interval. The patients as a whole group and the two randomised treatment groups were
compared at baseline to 1 year with primary outcome aortic distensibility and aforementioned secondary
outcomes on 1-year follow-up.
Myocardial perfusion analysis is not included in this report.
Following a protocol amendment, further analyses were conducted for patients stratified as responders or
non-responders to therapy according to Disease Activity Score-28 remission status.
All analyses were adjusted for baseline aortic distensibility, age, sex, systolic blood pressure and pack-years
smoking (± baseline Disease Activity Score-28-erythrocyte sedimentation rate as applicable). All analyses
were performed on 81 patients, with imputation of missing baseline and follow-up outcomes.
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Results
A total of 82 patients were enrolled into the CADERA study and underwent baseline cardiovascular
magnetic resonance imaging. In one participant no aortic distensibility data could be acquired. Of the
remaining 81 patients at baseline, 71 underwent a 1-year cardiovascular magnetic resonance scan.
A total of four patients were withdrawn from the study during the first year of follow-up, one because of
treatment non-compliance and the other three because of serious adverse events relating to treatment.
The reasons for the remaining six patients not undergoing a 1-year cardiovascular magnetic resonance
scan were refusal or claustrophobia (five patients) and moved away and not able to attend a repeat scan
(one patient). In total, 56 patients attended for a 2-year cardiovascular magnetic resonance scan.
Early rheumatoid arthritis patients and control subjects were of similar median [interquartile range] age
[51 (21) and 54 (23) years, respectively] and systolic blood pressure [121 (26) mmHg and 121 (14) mmHg,
respectively]. Median (interquartile range) erythrocyte sedimentation rate, C-reactive protein and Disease
Activity Score-28 in early rheumatoid arthritis patients were 30 (30) mm/hour, 8 (23) mg/l and 5.3 (1.4),
respectively. In total, 64 (84%) and 57 (75%) patients were anti-citrullinated peptide antibody and
rheumatoid factor positive, respectively. A total of 17 (22%), 25 (33%) and 34 (45%) patients in the
rheumatoid arthritis group were current, former and never smokers, respectively, and 4 (13%), 5 (17%)
and 21 (70%) patients in the control group were current, former and never smokers, respectively.
Primary objectives
Primary outcome
The primary outcome measure aortic distensibility [geometric mean (95% confidence interval)] was
significantly reduced in patients (n = 81) compared with control subjects (n = 30) [3.0 × 10–3/mmHg
(2.7 × 10–3/mmHg to 3.3 × 10–3/mmHg) vs. 4.4 × 10–3/mmHg (3.7 × 10–3/mmHg to 5.2 × 10–3/mmHg),
respectively; p < 0.01]. Aortic distensibility improved significantly from baseline to 1 year across the
whole patient cohort [3.0 × 10–3/mmHg (2.7 × 10–3/mmHg to 3.4 × 10–3/mmHg) vs. 3.6 × 10–3/mmHg
(3.1 × 10–3/mmHg to 4.1 × 10–3/mmHg), respectively; p < 0.01].
All differences remained significant when adjusted for age, sex, systolic blood pressure and pack-years smoked.
Secondary outcomes
Of the secondary outcome measures, left ventricular mass [geometric mean (95% confidence interval)] was
significantly lower in patients (n = 81) than in control subjects (n = 30) [78.2 g (74.0 to 82.7 g) vs. 92.9 g
(84.8 to 101.7 g), respectively; p < 0.01]. Left ventricular mass in patients increased from baseline to 1 year,
from 78.2 g (95% confidence interval 73.7 to 83.0 g) to 81.4 g (95% confidence interval 76.3 to 86.9 g;
p = 0.01). All differences remained significant when adjusted for age, sex, systolic blood pressure and
pack-years smoked.
Myocardial extracellular volume [geometric mean (95% confidence interval)] was significantly increased at
baseline in patients (n = 78) compared with control subjects (n = 30) [27.1% (26.4% to 27.9%) vs. 24.9%
(23.8% to 26.1%), respectively; p < 0.01]. This difference remained significant when adjusted for age, sex,
systolic blood pressure and pack-years smoked. Myocardial extracellular volume in patients (n = 81) decreased
from baseline to 1 year [geometric mean (95% confidence interval)], from 27.2% (26.4% to 28.1%) to 26.4%
(25.6% to 27.3%), but this difference was not statistically significant (p = 0.06).
Matched pairs analyses corroborated the significant differences between the control group and the
rheumatoid arthritis group for aortic distensibility, myocardial extracellular volume and left ventricular mass
(with left ventricular mass showing a consistent magnitude of change).
No significant differences were seen in the other secondary outcome measures between patients and
control subjects at baseline or in patients between baseline and 1 year of follow-up.
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Secondary objectives
At the 2-year follow-up time point, differences in the primary end point of aortic distensibility and in the
secondary end point of left ventricular mass were maintained. In addition, peak left ventricular twist
significantly increased from baseline to the 2-year follow-up, from a geometric mean of 14.9° (95% confidence
interval 14.0° to 15.9°) to a geometric mean of 16.6° (95% confidence interval 15.5° to 17.8°; p = 0.02).
As part of the additional analyses (following the protocol amendment), no significant differences in aortic
distensibility improvement were seen in the following comparisons (geometric means):
l group 1 (n = 40 at baseline) versus group 2 (n = 41 at baseline): 3.8 × 10–3/mmHg versus 3.4 × 10–3/mmHg;
p = 0.49
l combined group 1 and 2 non-responders (n = 38) versus combined group 1 and 2 responders (n = 43):
3.5 × 10–3/mmHg versus 3.6 × 10–3/mmHg; p = 0.87
l group 1 non-responders (n = 17) versus group 1 responders (n = 23): 3.6 × 10–3/mmHg versus 3.9 × 10–3/mmHg;
p = 0.73.
There was a trend towards a 10–30% difference between treatment strategies comparing group 1 responders
(n = 23) with group 2 responders (n = 13): geometric mean 3.9 × 10–3/mmHg versus 2.8 × 10–3/mmHg;
ratio 0.7 (95% confidence interval 0.4 to 1.2; p = 0.19); ratio adjusted for baseline aortic distensibility 0.8
(95% confidence interval 0.5 to 1.2; p = 0.29); ratio fully adjusted for baseline characteristics 0.9
(95% confidence interval 0.6 to 1.4; p = 0.56).
Discussion
The CADERA study presents the first evidence from a randomised controlled trial of the effects of DMARD
therapy on cardiovascular magnetic resonance imaging markers of cardiovascular disease in patients with
early, treatment-naive rheumatoid arthritis. The CADERA study has demonstrated that aortic distensibility,
a measure of aortic stiffness and a surrogate marker of cardiovascular disease risk, is lower in patients
with new-onset early rheumatoid arthritis than in control subjects. This finding suggests that cardiovascular
disease abnormalities are an early manifestation of rheumatoid arthritis, with potential implications for the
routine care of these patients.
The CADERA study has further shown that aortic distensibility improves at the 1- and 2-year follow-ups after
the initiation of DMARD therapy. Although there was no significant difference between the two treatment
regimes, first-line etanercept/methotrexate responders had a higher aortic distensibility at 1 year than first-line
methotrexate/csDMARD responders. This finding suggests that, in those patients who respond well to first-line
therapy, bDMARD treatment may be of further benefit. However, these preliminary findings are based on
modest patient numbers and require corroboration in future prospective studies.
Among the other cardiovascular magnetic resonance measures, we have demonstrated elevated myocardial
extracellular volume in patients compared with control subjects, which shows a trend towards improvement
after therapy. Myocardial extracellular volume is a marker of diffuse interstitial fibrosis and the elevated values
may relate to myocardial inflammation in early rheumatoid arthritis.
We have also observed lower baseline left ventricular mass in patients compared with control subjects
and an increase in left ventricular mass in patients from baseline to the 1- and 2-year follow-ups. This
observation may relate to the phenomenon of 'rheumatoid cachexia' caused by the reduced physical
activity in rheumatoid arthritis patients prior to the initiation of therapy.
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Conclusion
These randomised controlled trial data show changes in vascular function and myocardial composition
in treatment-naive early rheumatoid arthritis of < 12 months’ symptom duration compared with control
subjects. Optimal DMARD therapy (whether csDMARDs or bDMARDs) to control rheumatoid arthritis
disease activity is associated with significant improvements in aortic distensibility at 1 year. However,
aortic distensibility improvement appears not to be associated with response status per se (whether within
a treatment arm strategy or not). Exploratory evaluation suggests greater aortic distensibility improvement
with etanercept/methotrexate than with methotrexate (when controlling for response status).
Trial registration
This trial is registered as ISRCTN89222125 and ClinicalTrials.gov NCT01295151.
Funding
This project was funded by the Efficacy and Mechanism Evaluation programme, a Medical Research Council
and National Institute for Health Research (NIHR) partnership, and will be published in full in Efficacy and
Mechanism Evaluation; Vol. 8, No. 4. See the NIHR Journals Library website for further project information.
Pfizer supported the parent study, VEDERA, through an investigator-sponsored research grant reference
WS1092499.
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Chapter 1 Introduction
Parts of this text have been reproduced with permission from Plein et al.1 This is an open access articledistributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0)
license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license
their derivative works on different terms, provided the original work is properly cited, appropriate credit is
given, any changes made indicated, and the use is non-commercial. See: http://creativecommons.org/licenses/
by-nc/4.0/. The text below includes minor additions and formatting changes to the original text.
Background
Rheumatoid arthritis and cardiovascular disease
Rheumatoid arthritis (RA) is a chronic, progressive autoimmune disease that affects approximately 400,000
people in the UK. The life expectancy of patients with RA is reduced and the mortality rate is increased up
to threefold compared with the general population. This is largely because of the increased frequency of
premature cardiovascular disease (CVD), which accounts for up to 40% of mortality in RA patients and is
as high as that in patients with other major CVD risk factors, such as type 2 diabetes mellitus.2,3 It is now
widely accepted that CVD risk in RA is independent of and incremental to traditional cardiovascular (CV)
risk factors.4–6 European guidelines therefore suggest that, pending more definitive evidence, estimates
of CVD risk are multiplied by a factor of 1.5 for patients with RA.7,8
Rheumatoid arthritis time course and excess cardiovascular disease
Surrogate markers have been extensively applied to investigate CVD risk and outcomes in RA, partly
because of the challenges of delivering hard CV event end-point studies. Several studies have evaluated
subclinical and clinical evidence of atherosclerosis at the start of a RA diagnosis, although these are often
limited by modest participant numbers and the use of a variety of surrogate tools (endothelium-dependent
vasodilatory response and mainly ultrasound carotid intima–media thickness). One review concluded that
subclinical evidence of atherosclerosis and CV risk appear to exist at the time of diagnosis and overt events
gradually increase in incidence over time.9,10 A meta-analysis confirmed increased CVD mortality in RA but
not in a subgroup analysis of an inception cohort.11 Although the rate of CV events is low in the early
stages of RA, delayed diagnosis is associated with higher rates of CV events, with hypertension a strong
independent predictor of CV events.12
Rheumatoid arthritis-related inflammation and disease activity over time are associated with increased
CVD risk in patients with RA, which further highlights the importance of ensuring optimal and effective
disease control.12–15
Traditional CVD risk factors, systemic inflammation and RA-specific factors, and an interplay of this triad,
play a role in the increased risk. Although RA-specific factors have been implicated in the increased risk,
cumulative disease activity appears to be the strongest contributor to excess CVD risk.13
Therapeutic strategies in new-onset early rheumatoid arthritis
Current European League Against Rheumatism (EULAR) guidelines recommend that patients with newly
diagnosed RA are commenced on conventional synthetic disease-modifying anti-rheumatic drug (csDMARD)
therapy in combination with short-term glucocorticoids, with remission the ideal target (low disease activity
acceptable if remission is not considered achievable), as part of the ‘treat-to-target’ guidelines.14,15
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Biologic disease-modifying anti-rheumatic drug (bDMARD) therapy, including tumour necrosis factor
inhibitors (TNFis), is recommended only if csDMARDs, including methotrexate (MTX) (and, in the UK, at
least two csDMARDs), are tried and fail to confer adequate disease control, with escalation to bDMARD
therapy particularly advised in poorer prognostic groups. Strategy studies comparing first-line csDMARD
therapy in a treat-to-target approach with TNFi therapy show variable results, demonstrating equivalence
or superiority of first-line TNFi therapy. Improvements in radiographic evidence of joint disease and higher
rates of drug-free remission have been demonstrated with bDMARD therapy, as well as similar or slightly
greater remission induction rates.16–18 Long-term registry data have demonstrated a significant reduction in
the incidence of acute myocardial infarction in patients receiving TNFi compared with csDMARD therapy.19,20
Effect of rheumatoid arthritis disease-modifying anti-rheumatic drug
therapy on cardiovascular disease outcomes
There is significant focus on the extent to which effective RA disease control can also improve comorbidity,
especially CVD. Epidemiological studies have confirmed that RA disease-modifying anti-rheumatic drugs
(DMARDs) reduce CV events in RA patients. Systematic reviews have evaluated the reduction in CV events
with the use of MTX and TNFis, in particular, with relative risks in the range of 0.72 and 0.46–0.70,
respectively.21,22 Evaluation of any differential benefit of MTX as the anchor csDMARD and TNFi bDMARD
therapy has provided conflicting results, with some studies suggesting an equivalent benefit and others
indicating an additional benefit of a TNFi.19–21
Cardiovascular magnetic resonance studies in rheumatoid arthritis
Cardiovascular magnetic resonance (CMR) imaging is the most accurate test for detecting abnormalities
in myocardial and vascular function. CMR imaging studies of patients with RA have demonstrated
abnormalities in left ventricular (LV) remodelling.23–25 No studies have evaluated changes in LV myocardial
and vascular function in treatment-naive early RA. Furthermore, aside from the earlier mentioned cohort
studies, the impact of csDMARD and bDMARD therapy on the structure and function of the CV system in
RA has not been studied.
The VEDERA trial
The VEDERA (Very Early vs. Delayed Etanercept in early Rheumatoid Arthritis) trial was a phase IV,
pragmatic, single-centre, open-label randomised controlled trial of new-onset, treatment-naive early RA.
Participants were randomised to one of two first-line therapeutic strategies: (1) immediate TNFi therapy
(etanercept, ETN) and MTX or (2) MTX± additional csDMARD therapy in a treat-to-target approach,26 with
switch to delayed ETN and MTX in the event of failure to achieve clinical remission at 6 months. The primary
end point of the VEDERA trial was the difference in the proportion of patients in each treatment arm achieving
Disease Activity Score-28-erythrocyte sedimentation rate (DAS28-ESR) remission at 1 year. Secondary end
points included evaluation of the response to first-line ETN compared with delayed ETN (following MTX).
The CADERA study rationale
The CADERA (Coronary Artery Disease Evaluation in Rheumatoid Arthritis) study was a bolt-on study to the
VEDERA trial.23 The overarching objective was to evaluate whether or not patients with treatment-naive early
RA demonstrate myocardial and vascular changes on CMR imaging compared with matched control subjects;
whether or not such changes are modifiable with RA DMARD therapy; and whether or not bDMARD (TNFi)
therapy confers additional advantages over MTX/csDMARD therapy in modifying CV abnormalities.
INTRODUCTION
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The clinical unmet need
Individuals with RA are known to have an excess risk of CVD, equivalent to individuals with type 2
diabetes mellitus. Large epidemiological studies indicate that RA treatment improves CVD risk. No clinical
studies using accurate imaging have been performed on a controlled cohort of RA (early or established)
to determine the presence, extent and type of CV abnormalities compared with control subjects, whether
or not RA disease control using DMARDs improves these CV abnormalities and whether or not RA
treatment type is relevant. The CADERA study was the first study to use CMR imaging to address these
questions and, in doing so, will help to inform future management of patients with early RA.
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Chapter 2 Clinical trial methods
Objectives
Primary objectives
l To determine if CV abnormalities, as assessed by CMR imaging, are present in a treatment-naive
inception cohort of early RA patients compared with control subjects.
l To establish whether or not (any) RA DMARD strategy is associated with improvement in CV
abnormalities, as measured by CMR imaging, in a treatment-naive inception cohort of early RA patients
over a 1-year period.
l To establish whether or not TNFi therapy confers a quantitative difference in the incidence of CVD
compared with standard therapy, as measured by CMR imaging, in a treatment-naive inception cohort
of early RA patients over a 1-year period.
Secondary objectives
l To determine changes in CV abnormalities, as assessed by CMR imaging, in a treatment-naive inception
cohort of early RA patients over a 2-year period.
l Improvement in CV abnormalities relative to RA disease control (based on response status) and also each
treatment strategy (initial TNFi/MTX vs initial csDMARD including MTX). This was an additional analysis
undertaken as part of a protocol amendment.
Exploratory objectives (not included in this report and subject to separate funding)
l To undertake bolt-on studies on biological samples (blood) collected from all patients recruited into the
study to identify RA patients with a high-risk profile for preclinical CVD and identify candidate markers
and shared mechanisms.
l To link CMR imaging findings to clinical outcomes through long-term follow-up in a longitudinal
observational registry.
Design
The study was a longitudinal, observational CMR imaging study that bolted onto the parent VEDERA trial,
a phase IV, pragmatic, single-centre, open-label randomised controlled trial of new-onset, treatment-naive
early RA comparing the clinical effectiveness of two different first-line therapeutic strategies.23 Participants
were randomised to one of two first-line therapeutic strategies: (1) immediate TNFi therapy (ETN) and MTX
or (2) MTX ± additional csDMARD therapy in a treat-to-target approach, with a switch to delayed ETN
and MTX in the event of failure to achieve clinical remission at 6 months. The primary end point was the
comparison of the proportion of patients in each treatment arm to achieve DAS28-ESR remission. Secondary
end points included evaluation of the response to first-line ETN compared with delayed ETN (following MTX).
The VEDERA trial participants who also consented to the CADERA substudy underwent CMR scans at
baseline (prior to the commencement of randomised RA treatment) and at 1 and 2 years after enrolment.
The study was reviewed and approved by the National Research Ethics Service Research Ethics Committee
Leeds (West) (reference 10/H1307/138).
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Patient and public involvement
Mrs Ailsa Bosworth, Chief Executive and founder of the National Rheumatoid Arthritis Society (NRAS), was
the patient and public involvement (PPI) contributor on the Trial Steering Group. Through membership of
the Trial Steering Committee, the PPI contributor also provided input into the conduct of the trial as needed;
this ensured a patient-centred approach to maximise the chance of obtaining patient therapeutic benefits.
Participants
Patients were recruited between February 2012 and November 2015 from a single tertiary centre, an early
RA rheumatology outpatient clinic (Chapel Allerton Hospital, Leeds, UK). Consecutive patients diagnosed
with new-onset RA according to American College of Rheumatology (ACR)/EULAR 2010 criteria27 were
invited to enrol into the VEDERA randomised controlled trial23 and the parallel CADERA CVD substudy.24
Thirty control subjects (free of CVD) were recruited through local advertisements, e-mail shots and word of
mouth. From the responders, those of similar age and sex distribution to the study subjects were selected.
Exclusion criteria were any history of rheumatological and/or CVD.
Eligibility
The VEDERA inclusion criteria
The VEDERA inclusion criteria were no previous use of DMARD therapy, a symptom duration of ≤ 1 year,
a DAS28-ESR of ≥ 3.2 and at least one poor prognostic factor [positive for anti-citrullinated peptide
antibody (ACPA) ± rheumatoid factor (RF) or, in ACPA- and RF-negative individuals, the presence of
abnormal power Doppler in any joint].
The VEDERA exclusion criteria
The VEDERA exclusion criteria were previous use of DMARD therapy, contraindications to TNFi therapy or
patients considered clinically unsuitable for TNFi therapy by the treating physician.
Additional CADERA exclusion criteria
Additional CADERA exclusion criteria were renal failure (estimated glomerular filtration rate < 30 ml/minute/
1.73 m2), contraindications to intravenous adenosine (asthma or high-grade atrioventricular block), a known
allergy to gadolinium-based contrast agent, claustrophobia, a weight of ≥ 120 kg and a metallic implant/
foreign body deemed unsafe for CMR imaging.
Interventions
This observational study bolted onto the parent VEDERA trial, which included the following 1-year duration
randomised intervention treatment arms:
l experimental treatment arm (group 1) – ETN group: immediate ETN and MTX treatment
l control treatment arm (group 2) – standard treatment group: initial MTX monotherapy with a treat-to-
target regimen – escalation to combination conventional synthetic DMARD therapy at or after 8 weeks
(up to week 24) if failing to meet the predefined target at 4-weekly assessments, and if failing to meet
the predefined target of clinical remission at week 24, step up to bDMARD, ETN and MTX.
Etanercept (Enbrel®, Pfizer Inc., New York, NY, USA) is a human tumour necrosis factor (TNF) receptor
p75Fc fusion protein produced by recombinant deoxyribonucleic acid (DNA) technology. MTX and/or
additional csDMARDs include sulfasalazine and hydroxychloroquine.
CLINICAL TRIAL METHODS
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After week 48, participants on ETN stopped therapy and standard of care treatment was maintained for
the year 2 observational period.
Study procedures
Following written informed consent (to participate in the VEDERA and the CADERA studies) and prior to
any trial-related procedures for the CADERA study, patients were registered into the CADERA study. All
patients underwent screening within the 4 weeks prior to the baseline visit for the VEDERA trial. At the
baseline visit eligibility for the study was confirmed, patients were randomised to one of the treatment
groups and study treatment was initiated. Further visits, which included assessment of disease activity, took
place at weeks 4, 12 and every 12 weeks thereafter, up to week 96, for both treatment arms, with additional
visits (for group 2) at weeks 8, 16 and 20 for safety and efficacy evaluation within a treat-to-target protocol.
At baseline and at 1 and 2 years following initiation of therapy, all patients recruited to the CADERA study
also underwent comprehensive CMR imaging.
Cardiovascular magnetic resonance imaging protocol
Each CMR imaging study was conducted using the same protocol. Imaging took approximately 1 hour.
The CMR imaging protocol included:
l cine imaging in a stack of LV short-axis sections covering the entire heart for measurement of
ventricular volumes and LV mass (LVM)
l MR tagging in three LV short-axis sections to derive LV longitudinal strain and twist
l cine imaging of the thoracic aorta to allow measurement of aortic distensibility (AD)
l adenosine stress and rest first-pass perfusion imaging using a dual-bolus technique, with intravenous
infusion of 0.01 and 0.1 mmol/kg gadopentate dimeglumine (Magnevist®, Bayer, Berlin, Germany) –
this part of the protocol was optional for patients and the results are not reported here
l T1 mapping (modified look-locker inversion recovery method) pre and 10 minutes post contrast to
derive the myocardial extracellular volume (MECV) fraction
l late gadolinium enhancement (LGE) imaging.
Outcome measures
Primary outcome measure
The primary outcome measure for the study was AD, a measure of aortic stiffness. This was chosen
because of its dynamic nature, high reproducibility and ability to predict major CV events independently of
traditional clinical risk scoring models in patients with no known CVD.32 The normality of data were tested
using a Shapiro–Wilk test.
Secondary outcome measures
l Left ventricular ejection fraction (LVEF).
l Left ventricular longitudinal strain (LVLS).
l Left ventricular twist.
l Left ventricular mass.
l Myocardial perfusion reserve (not reported here).
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Exploratory outcome measures
l Myocardial extracellular volume fraction from T1 mapping.
l Biomarkers of CVD (as part of future biological studies; not reported here).
Patient withdrawal
Patients could withdraw from the study at any time without explanation and continue to receive treatment
as per standard clinical practice. Patient withdrawal was categorised as withdrawing consent for further
study follow-up evaluation only, but willing to have CMR imaging data to date kept and used.
Sample size and power calculation
The sample size estimation for the primary end point AD was based on previous work by Ikonomidis et al.,23
which showed improved AD in RA patients in response to interleukin-1 therapy. We calculated that 33
patients in each treatment group would equate to an 80% power to detect a difference in AD between
the two treatment groups at a 5% significance level.
Blinding
The CMR fellows analysing the CMR scans were blinded to the VEDERA treatment allocation.
Analysis
Statistical analysis
The first 30 CADERA patients (cases) were approximately matched by age and sex to control subjects,
who were invited for a CMR scan. Matched pairs analysis was conducted on the primary outcome (AD),
secondary outcomes [LVEF, LVLS, peak left ventricular twist (PLVTw)] and exploratory outcome (MECV)
at baseline. To reflect the approximate matching, additional linear regression analyses are presented for
each of the primary, secondary and exploratory outcomes at baseline including the 30 control subjects
and all cases when data are available. Each analysis is presented unadjusted (with a single independent
variable case/control) and adjusted (with dependent variables of case/control, age, sex, systolic blood
pressure and pack-years smoked). Outcomes are natural log transformed to achieve normality assumptions
(an approach favoured over non-parametric analysis to allow straightforward adjustment in the additional
regression analyses and consistency with the analyses at the 1-year and 2-year follow-ups. Back-transformation
is performed when presenting results [thus, geometric mean ratios and associated 95% confidence intervals
(CIs) are reported]. To assess the balance of demographic characteristics across all cases and the 30 control
subjects, summary statistics are presented for age, sex, systolic blood pressure and pack-years smoked.
For analysis of the primary, secondary and exploratory outcomes in the CADERA patients at the 1-year and
2-year follow-ups, an analysis of covariance (ANCOVA) method has been adopted. The outcome at follow-up
is linearly regressed on a grouping variable (defined below) as the dependent variable, first as an unadjusted
analysis (exploring differences in the outcome by group at 1 year or 2 years), second, additionally adjusted
for baseline outcome (an ANCOVA approach to analysis of change, replacing the differences from baseline
method originally proposed) and, third, additionally adjusted for baseline outcome, age, sex, systolic blood
pressure, pack-years smoked and, where appropriate (see below), baseline DAS28-ESR (again, an ANCOVA
approach to analysis of change, replacing the differences from baseline method originally proposed). The
change of approach compared with the CADERA study protocol, from differences from baseline to an
CLINICAL TRIAL METHODS
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ANCOVA approach, was undertaken to enhance the power, given the additional grouped analyses to
be undertaken (see below). Outcomes are naturally log transformed to achieve normality assumptions.
Back-transformation is performed when presenting results and thus estimates are geometric means or ratios
across groups.
Groups were defined as follows, in which group 1 patients received first-line ETN/MTX and group
2 patients received first-line MTX ± additional csDMARD therapy that either continued (2a) or escalated
to delayed ETN/MTX (2b) at week 24. The intention of these subgroup analyses was to determine any
differences between patients who were treated with first-line ETN and those who never received ETN:
(a) group 1 (all patients) compared with group 2 (all patients)
(b) combined group 1 and group 2 responders compared with combined group 1 and group 2
non-responders, adjusting for baseline DAS28-ESR
(c) group 1 responders compared with group 1 non-responders, adjusting for baseline DAS28-ESR
(d) group 1 responders compared with group 2a responders, adjusting for baseline DAS28-ESR.
Patients with a DAS28-ESR of ≥ 2.6 at 48 weeks were considered non-responders. Patients with DAS28-ESR
of < 2.6 at week 48 for reasons other than withdrawal for lack of efficacy were assumed to be responders
in the initial analysis. The data were then reanalysed assuming that they were non-responders.
For an intention-to-treat analysis, multiple imputation by chained equations was used to create 50 complete
data sets per outcome analysed, the results from which were combined in accordance with Rubin’s rules.
The imputation model included the following variables at weeks 0, 12, 24, 36 and 48: Swollen Joint Count-
28 joints (SJC44), Ritchie Articular Index (RAI), C-reactive protein (CRP), ESR, physician visual analogue scale
(VAS), patient general health VAS, patient pain VAS, patient disease activity VAS and early morning stiffness.
Outcome values at 1 or 2 years were included (dependent on outcome analysed) in addition to baseline
values. The model also included age, sex, systolic blood pressure, pack-years smoked, symptom duration,
treatment and an indicator for whether or not a patient was a responder (as defined above). Multiple
imputation chain mixing and distribution diagnostics were checked for plausibility of imputations.
For the primary outcome (AD) at 1 year only, an analysis adjusted for area under the curve (AUC) disease
activity is reported. A trapezoid rule is used based on DAS28-ESR at weeks 0, 12, 24, 36 and 48 to
calculate the AUC. The imputation model for this analysis excluded the indicator variable for whether or
not a patient was a responder.
For comparison, demographics are presented for those CADERA patients who have at least one primary,
secondary or exploratory outcome missing at the 1-year or 2-year follow-up and those CADERA patients
who have complete data for all outcomes at 1 year and 2 years.
Where relevant, protocol amendments (see Appendix 4) informed any change and/or additional analyses.
Cardiovascular magnetic resonance analysis
All post-processing analysis of CMR scans was performed using CVI 42 software (Circle Cardiovascular
Imaging, Calgary, Canada) except for tagging analysis by assessors with > 2 years’ experience in CMR
imaging reporting blinded to all patient details.
l AD was calculated from cross-sectional cine images of the thoracic aorta at the level of the pulmonary
artery bifurcation. The endocardial aortic border was delineated in both diastole and systole. AD was
calculated as follows: Δ relative aortic cross-sectional area/Δ systolic and diastolic blood pressure.
l The LV endocardial and epicardial borders were manually traced from the short-axis LV cine stack at
both end-systole and end-diastole. The LV end-systolic and end-diastolic volumes were generated by
summation of discs and the LVEF calculated. The LVM was calculated from the end-diastolic myocardial
volume, with trabeculation and papillary muscles excluded.
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l Tagged images were analysed with inTag software version 1.0 (Creatis, Lyon, France). Endocardial and
epicardial borders were outlined. Peak circumferential strain and rotation were calculated for three
slices. PLVTw was calculated by subtracting basal from apical rotation. LVLS was defined as peak LV
systolic annular velocity ('Mid LV S prime').
l Pre-contrast and post-contrast T1 was measured in a region of interest in the interventricular septum
of the midventricular slice. The venous haematocrit (Hct) was used to calculate the MECV fraction
according to the following equation:
MECV = (1 – Hct) × ((1/myocardial post contrast T1(milliseconds) – (1/myocardial native T1(milliseconds))/
((1/blood post-contrast T1(milliseconds)) – (1/blood pre-contrast T1(milliseconds)). (1)
CLINICAL TRIAL METHODS
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Chapter 3 Clinical trial results
Patient recruitment
Patient numbers
A total of 82 patients were enrolled into the CADERA study and underwent the baseline CMR scan. In one
patient, no AD data could be acquired (but all other assessments were completed). Of the 81 patients with
complete baseline data, 71 underwent a 1-year CMR scan (Figure 1) and 56 underwent a 2-year scan.
In total, the 30 control subjects matched for sex and age to the first 30 CADERA patients were recruited.
Withdrawals
A total of four patients were withdrawn from the study between baseline and 1 year of follow-up; one
patient withdrew because of treatment non-compliance and the other three patients withdrew because
of serious adverse events relating to treatment. The reasons for the remaining six patients not undergoing a
1-year CMR scan included refusal or claustrophobia (five patients) and moving away and not able to attend
a repeat scan (one patient).
Baseline demographic data
Demographic data for the control subjects and the CADERA study cohort are presented in Table 1. The
baseline characteristics were balanced across the two treatment groups with the exception of median
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• Serious adverse
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• Unable/refused, n = 5
• No clinical response
   to treatment, n = 1
• Treatment
   non-compliance, n = 1
FIGURE 1 Study recruitment flow chart.
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As detailed earlier, 71 patients attended for the 1-year scan and 56 attended for the 2-year scan. Table 2
details the key demographic data relevant for the primary outcome, split by those with complete data for
all outcomes and those who had at least one missing outcome. No notable differences were observed
between these two groups.









Group 1,a n (%)
or n (median,
interquartile range)
Group 2,a n (%)
or n (median,
interquartile range)








Age (years) 30 (54, 23) 81 (51, 21) 40 (48.5, 13.5) 41 (54, 23)
BMI (kg/m2) 30 (27.0, 7.1) 81 (24.9, 5.4) 40 (25.6, 5.5) 41 (24.6, 5.2)
ESR (mm/hr) N/A 77 (30, 30) 39 (31, 33.5) 38 (30, 28.3)
CRP (mg/l) N/A 77 (8, 23) 39 (8, 27) 38 (8, 17.8)












Baseline DAS28-ESR N/A 76 (5.3, 1.4) 38 (5.5, 1.6) 38 (5.3, 1.4)




























30 (120.5, 13.5) 81 (121, 26) 40 (122, 24.5) 41 (120, 23)
Pack-years smoking 30 (0, 0.4) 81 (0.1, 10) 40 (0, 5.3) 41 (3, 17.5)












BMI, body mass index; CCP, cyclic-citrullinated peptide; IHD, ischaemic heart disease; N/A, not applicable.
a Group 1: immediate ETN and MTX treatment; group 2: first-line MTX ± additional csDMARD therapy.
TABLE 2 Key demographics split by patients with at least one missing outcome at 1 year or 2 years
Demographic variable
At least one missing outcome,
n (%) or n (median, interquartile range)
Complete data for all outcomes,
n (%) or n (median, interquartile range)
Age (years) 37 (45, 18) 44 (53, 18.25)
Sex Male 9 (25), female 27 (75) Male 16 (36), female 28 (64)
Systolic blood pressure (mmHg) 37 (115, 21) 44 (123, 26)
Pack-years smoking 37 (1, 15) 44 (0.1, 8.1)
CLINICAL TRIAL RESULTS
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Primary objectives
Patients compared with control subjects
The primary objective of the CADERA study was to determine if CV abnormalities, as assessed by
CMR imaging, are present in a treatment-naive inception cohort of early RA patients compared with
control subjects.
The primary outcome measure AD [geometric mean (95% CI)] was significantly lower in patients (n = 81)
than in control subjects (n = 30) [3.0 × 10–3/mmHg (2.7 × 10–3/mmHg to 3.3 × 10–3/mmHg) vs. 4.4 × 10–3/mmHg
(3.7 × 10–3/mmHg to 5.2 × 10–3/mmHg), respectively; p < 0.01] (Table 3). This difference remained significant
when adjusted for age, sex, systolic blood pressure and pack-years smoked.
Of the secondary outcome measures, LVM [geometric mean (95% CI)] was significantly lower in patients
(n = 81) than in control subjects (n = 30) [78.2 g (74.0 to 82.7 g) vs. 92.9 g (84.8 to 101.7 g), respectively;
p < 0.01]. MECV [geometric mean (95% CI)] was significantly increased at baseline in patients (n = 78)
compared with control subjects (n = 30) [27.1% (26.4% to 27.9%) vs. 24.9% (23.8% to 26.1%),
respectively; p < 0.01]. These differences remained significant when adjusted for age, sex, systolic blood
pressure and pack-years smoked. No significant differences between patients and control subjects were
seen in the other secondary outcome measures.
Matched pairs analyses corroborated the significant differences between the control group and the early
RA group for AD, MECV and LVM (with a consistent magnitude and direction in the difference for LVM)
(Table 4). Three patients were excluded because of screen failure for the VEDERA trial; thus, a maximum of
27 matched pairs were available for analysis.
These data were partly presented at the American College of Rheumatology meeting.28
Early rheumatoid arthritis cohort: baseline to 1 year
All analyses were performed on 81 patients, with imputation of missing baseline and follow-up outcomes
as described in Chapter 2.
A further primary objective of the CADERA study was to establish whether or not (any) RA DMARD
strategy is associated with improvement in CV abnormalities over a 1-year period (Table 5).




















111 4.4 (3.7 to 5.2) 3.00 (2.7 to 3.3) 1.5 (1.2 to 1.8) < 0.01 1.5 (1.3 to 1.7) < 0.01
LVEF (%) 111 61.6 (59.7 to 63.7) 60.3 (59.2 to 61.5) 1.0 (1.0 to 1.1) 0.27 1.0 (1.0 to 1.1) 0.38
LVLS
(cm/second)
106 1.1 (1.1 to 1.2) 1.1 (1.1 to 1.2) 1.0 (1.0 to 1.1) 0.76 1.0 (0.9 to 1.1) 0.95
PLVTw (°) 106 15.3 (13.9 to 16.9) 15.1 (14.1 to 16.0) 1.0 (0.9 to 1.2) 0.71 1.0 (0.9 to 1.2) 0.69
LVM (g) 111 92.9 (84.8 to 101.7) 78.2 (74.0 to 82.6) 1.2 (1.1 to 1.3) < 0.01 1.2 (1.1 to 1.3) 0.03
MECV (%) 108 24.9 (23.8 to 26.1) 27.2 (26.4 to 27.9) 0.9 (0.9 to 1.0) < 0.01 0.9 (0.9 to 1.0) < 0.01
a Adjusted for age, sex, systolic blood pressure and pack-years smoked.
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The primary outcome measure, AD [geometric mean (95% CI)], improved significantly from baseline to 1 year
across the whole patient cohort [3.0 × 10–3/mmHg (2.7 × 10–3/mmHg to 3.4 × 10–3/mmHg) vs. 3.6 × 10–3/mmHg
(3.1 × 10–3/mmHg to 4.1 × 10–3/mmHg), respectively; p < 0.01]. This difference remained significant when
adjusted for age, sex, systolic blood pressure and pack-years smoked.
Left ventricular mass in the combined groups 1 and 2 cohort increased from baseline to the 1-year follow-up,
from a geometric mean of 78.2 g (95% CI 73.7 to 83.0 g) to 81.4 g (95% CI 76.3 to 86.9 g; p = 0.01), but
no significant between group differences were observed. This difference remained significant when adjusted
for age, sex, systolic blood pressure and pack-years smoked.
Myocardial extracellular volume decreased from baseline to 1 year, from a geometric mean of 27.2%
(95% CI 26.4% to 28.1%) to 26.4% (95% CI 25.6% to 27.3%), but this difference was not statistically
significant (p = 0.06).
There were no significant changes in the other secondary outcome measures between baseline and the
1-year follow-up.
Early compared with delayed etanercept and methotrexate
A third primary objective of the CADERA study was to establish whether or not TNFi therapy confers a
quantitatively superior difference (improvement) in CVD, as measured by CMR imaging, compared with
standard therapy in a treatment-naive inception cohort of early RA patients over a 1-year period. There
was no statistically significant difference in AD change at 1 year when comparing the two treatment
groups (Table 6).





(95% CI), 1 year Ratio (95% CI); p-value
AD (10–3/mmHg) 3.0 (2.7 to 3.4) 3.6 (3.1 to 4.1) 1.2 (1.1 to 1.3); 0.01
LVEF (%) 60.3 (59.1 to 61.6) 59.9 (58.5 to 61.5) 1.0 (1.0 to 1.0); 0.54
LVLS (cm/second) 1.1 (1.1 to 1.2) 1.1 (1.1 to 1.2) 1.0 (1.0 to 1.1); 0.84
PLVTw (°) 14.9 (13.9 to 15.8) 14.6 (13.7 to 15.7) 1.0 (0.9 to 1.1); 0.69
LVM (g) 78.2 (73.7 to 82.9) 81.4 (76.3 to 86.9) 1.0 (1.0 to 1.1); 0.01
MECV (%) 27.2 (26.4 to 28.1) 26.4 (25.6 to 27.1) 1.0 (0.9 to 1.0); 0.06
N = 81, with imputation for missing baseline or follow-up values.
TABLE 4 Matched pairs analyses of outcomes at baseline
Outcome n
Ratio (control/case),
geometric mean (95% CI) p-value
AD (10–3/mmHg) 27 1.5 (1.15 to 2.00) < 0.01
LVEF (%) 27 1.0 (1.0 to 1.1) 0.23
LVLS (cm/second) 25 1.0 (1.0 to 1.1) 0.35
PLVTw (°) 25 1.0 (0.9 to 1.2) 0.78
LVM (g) 27 1.2 (1.0 to 1.3) 0.07
MECV (%) 25 0.9 (0.8 to 0.9) < 0.01
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A secondary objective of the CADERA study was to explore whether or not the DAS28-ESR29 control and
associated response status (DAS28-ESR remission-defined clinical response/non-response) affects changes
in CV abnormalities over a 1-year period.
There were no differences when all responders were compared with non-responders and when group 1
responders were compared with non-responders (all adjusted for baseline AD, age and sex) (see Table 6).
To clarify this apparent absence of effect of disease activity as represented by response status, correlation
analyses between AUC disease activity and AD at year 1 in the combined groups 1 and 2 (Table 7) and
between group 1 and group 2 (Table 8) were carried out; these also did not identify an association.






Ratio (95% CI); p-value
Unadjusted Adjusted 1b Adjusted 2c
Combined groups 1 and 2 (n = 81):
baseline, 1 year
3.0 (2.7 to 3.4),
3.6 (3.1 to 4.1)
1.2 (1.1 to 1.3);
< 0.01
N/A N/A
Group 1 at 1 year (all, n = 40) vs. group 2
at 1 year (all, n = 41)
3.8 vs. 3.4 0.9 (0.7 to 1.2);
0.49
0.9 (0.7 to 1.2);
0.42
0.9 (0.8 to 1.2);
0.56
Combined groups 1 and 2 at 1 year
(non-responders, n = 38) vs. combined
groups 1 and 2 at 1 year (responders,
n = 43)
3.5 vs. 3.6 1.0 (0.8 to 1.4);
0.87
1.0 (0.8 to 1.2);
0.79
1.0 (0.8 to 1.2);
0.86
Group 1 at 1 year (non-responders,
n = 17) vs. group 1 at 1 year
(responders, n = 23)
3.6 vs. 3.9 1.1 (0.7 to 1.6);
0.73
1.0 (0.7 to 1.3);
0.84
1.0 (0.7 to 1.3);
0.82
Group 1 at 1 year (responders, n = 23)
vs. group 2a at 1 year (responders,
n = 13)
3.9 vs. 2.8 0.7 (0.4 to 1.2);
0.19
0.8 (0.5 to 1.2);
0.29
0.9 (0.6 to 1.4);
0.56
N/A, not applicable.
a Group 1: immediate ETN and MTX treatment; group 2: first line MTX± additional csDMARD therapy; group 2a: group 2
patients who continued csDMARD therapy and did not escalate to delayed ETN/MTX at week 24; non-responders:
patients with a DAS28-ESR ≥ 2.6 at 48 weeks; responders: patients with DAS28-ESR of < 2.6 at 48 weeks.
b Adjusted 1: adjusted for baseline AD.
c Adjusted 2: adjusted for baseline AD, age, sex, systolic blood pressure and pack-years smoking (± baseline DAS28-ESR
as applicable).
Response assumed for patients whose responder status at 48 weeks was unknown.
TABLE 7 Regression analyses between AD at 1 year and AUC disease activitya
Patient group
AD-to-AUC disease activity ratio (95% CI); p-value
Unadjusted Adjusted 1b Adjusted 2c
All RA patients (n = 81) 1.1 (0.8 to 1.5); 0.60 1.0 (0.8 to 1.3); 0.70 1.1 (0.8 to 1.3); 0.69
a Coefficients presented per 100-unit increase in AUC.
b Adjusted 1: additionally adjusted for baseline AD.
c Adjusted 2: additionally adjusted for baseline AD, age, sex, systolic blood pressure and pack-years smoking.
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Comparison of (group 1) responders who received ETN as first-line therapy and (group 2) responders who
never received ETN (group 2a) showed an unadjusted difference of 30% (ratio 0.7, 95% CI 0.4 to 1.2);
the difference was 19% when adjusted for baseline AD (ratio 0.8, 95% CI 0.5 to 1.2) and 10% when
adjusted for possible confounders (ratio 0.9, 95% CI 0.60 to 1.18), although these differences are not
statistically significant (see Table 6).
Two-year follow-up
A further secondary objective of the CADERA study was to establish if any treatment effects of RA therapy
are sustained over a 2-year period. The difference in the primary outcome measure, AD, was maintained at
the 2-year follow-up [geometric mean (95% CI): 3.0 × 10–3/mmHg (2.7 × 10–3/mmHg to 3.4 × 10–3/mmHg)
vs. 3.6 × 10–3/mmHg (3.1 × 10–3/mmHg to 4.1 × 10–3/mmHg), respectively; p = 0.05] (Table 9). As in the
year 1 analysis, there were no differences between responders and non-responders. The comparison of
group 1 responders and group 2a responders showed a smaller difference than in year 1 (see Table 9).





Ratio (95% CI); p-value
Unadjusted Adjusted 1b Adjusted 2c
Group 1 (all, n = 40) vs. group 2
(all, n = 41)
3.8 vs. 3.4 0.9 (0.7 to 1.2);
0.48
0.9 (0.7 to 1.1);
0.41
0.9 (0.7 to 1.2);
0.45
a Group 1: immediate ETN and MTX treatment; group 2: first-line MTX ± additional csDMARD therapy.
b Adjusted 1: adjusted for baseline AD.
c Adjusted 2: adjusted for baseline AD, age, sex, systolic blood pressure, pack-years smoking and AUC disease activity.





Ratio (95% CI), p-value
Unadjusted Adjusted 1b Adjusted 2c
Combined groups 1 and 2 (n = 81):
baseline, 2 years
3.0 (2.7 to 3.4),
3.6 (3.1 to 4.1)
1.1 (1 to 1.4),
0.05
N/A N/A
Group 1 at 2 years (all, n = 40) vs.
group 2 at 2 years (all, n = 41)
3.7 vs. 3.4 0.9 (0.7 to 1.2),
0.59
0.9 (0.7 to 1.2),
0.6
0.9 (0.7 to 1.2),
0.65
Combined groups 1 and 2 at 2 years
(non-responders, n = 38) vs. combined
groups 1 and 2 at 2 years (responders,
n = 43)
3.5 vs. 3.6 1.0 (0.8 to 1.4),
0.83
1.0 (0.8 to 1.4),
0.91
1.0 (0.7 to 1.4),
0.95
Group 1 at 2 years (non-responders,
n = 17) vs. group 1 at 2 years (responders,
n = 23)
3.5 vs. 3.8 1.1 (0.7 to 1.7),
0.75
1.1 (0.6 to 1.7),
0.83
1.1 (0.6 to 1.8),
0.83
Group 1 at 2 years (responders, n = 23)
vs. group 2a at 2 years (responders,
n = 13)
3.8 vs. 3.4 0.9 (0.6 to 1.4),
0.56
0.9 (0.6 to 1.5),
0.70
0.9 (0.5 to 1.6),
0.70
N/A, not applicable.
a Group 1: immediate ETN and MTX treatment; group 2: first-line MTX ± additional csDMARD therapy; group 2a: group 2
patients who continued csDMARD therapy and did not escalate to delayed ETN/MTX at week 24; non-responders:
patients with DAS28-ESR ≥ 2.6 at 48 weeks; responders: patients with DAS28-ESR of < 2.6 at 48 weeks.
b Adjusted 1: adjusted for baseline AD.
c Adjusted 2: adjusted for baseline AD, age, sex, systolic blood pressure and pack-years smoking (± baseline DAS28-ESR
as applicable).
Response assumed for patients whose responder status at 48 weeks was unknown.
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The difference in LVM remained significant from baseline to the 2-year follow-up [geometric mean (95% CI):
78.2 g (73.7 to 82.9 g) vs. 85.5 g (79.0 to 92.6 g), respectively; p = 0.02] (see Appendix 3, Table 17). Of the
other secondary outcome measures, PLVTw showed a significant difference from baseline to the 2-year
follow-up [geometric mean (95% CI): 14.9° (14.0° to 15.9°) vs. 16.6° (15.5° to 17.8°), respectively; p = 0.02]
(see Appendix 3, Table 15). There were no differences between the treatment arms and no other parameters
showed statistically significant differences at the 2-year follow-up. Appendix 3 (Tables 10–20) details all
secondary measures at years 1 and 2.
Ten RA patients had abnormal findings on LGE imaging and/or follow-up CMR imaging. In eight patients
inferior right ventricular insertion point enhancement was seen and in two patients there was septal
enhancement.
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The CADERA study was the first prospectively conducted single-centre randomised controlled trial toassess the impact of modern DMARD therapy on CMR imaging markers of subclinical CVD in patients
with newly diagnosed, treatment-naive, very early RA and no previous history of CVD.
The study has demonstrated that AD, a measure of aortic stiffness and a surrogate marker for increased
risk of CVD, is lower in patients with a recent new diagnosis of RA than in control subjects. Other markers
of CVD, in particular those related to inflammation, including elevated native T1 and extracellular volume
(ECV) in CMR imaging, were raised and LVM was reduced compared with control subjects. Treatment for
RA, irrespective of strategy, improved AD at 1 and 2 years, whereas first-line treatment with TNFi bDMARD
(ETN) showed the potential for additional benefits in those patients who responded to treatment.
Baseline assessment
Several previous studies have demonstrated reduced aortic stiffness using a variety of non-invasive imaging
techniques in patients with established RA. A cross-sectional study of RA patients in clinical remission
showed lower augmentation index values than in patients with active RA.23 Another study showed that
a high augmentation index and aortic pulse wave velocity values were predictive of CV events in 138
patients over a 6-year follow-up period.30 The CADERA study is the first study to demonstrate changes in
vascular function compared with control subjects in newly diagnosed RA patients with a symptom duration
of < 12 months. The observation that CVD is already manifest at such an early disease stage should
motivate the commencement of CVD risk modification at the time of RA diagnosis.
We used CMR imaging to detect other subclinical CVD in the CADERA cohort. CMR imaging is considered
to be the most accurate test for measuring left and right ventricular dimension, function and mass, and
allows non-invasive tissue characterisation using cine, LGE and parametric mapping methods. Previous
studies using CMR imaging have shown a range of abnormalities in patients with established RA, including
lower LVM compared with control subjects, higher native T1 and ECV, indicative of diffuse oedema and/or
myocardial fibrosis, focal fibrosis on LGE imaging and lower LV strain, indicating diastolic myocardial
impairment.31,32 Native T1, ECV and strain correlated with disease activity.
The CADERA study has shown that changes in these parameters compared with control subjects are already
present in patients with new-onset early RA, suggesting that the relatively short period of generalised
inflammation is sufficient to cause measurable and widespread CV changes. In effect, this refers to the
period of generalised inflammation from the time of onset of symptoms, preceding presentation and the
diagnosis of RA, leading to measurable CV effects at the point of diagnosis.
The observed reduced myocardial muscle mass in RA in the CADERA study and previous studies may be the
consequence of myocardial collagen deposition in response to elevated TNF or a process called ‘rheumatoid
cachexia’. A combination of inflammation and reduced physical activity in RA patients, which leads to reduced
skeletal muscle mass in combination with increased fat mass, is a key driver of rheumatoid cachexia. It is
possible that the reduction in muscle mass extends beyond skeletal muscle to involve the myocardium in
patients with rheumatoid cachexia.
Patients had a higher MECV than control subjects. MECV is a measure of diffuse myocardial fibrosis and
has been reported to be elevated in patients with established RA.31 Our data suggest that, even in an
inception cohort of RA, myocardial fibrosis is present. MECV has emerged as a potentially useful biomarker
of disease and indicator of poor prognostic outcome in the general ischaemic heart disease population.
Longitudinal studies may similarly suggest a role in RA populations. In addition, a small proportion (14%)
of the CADERA patients showed non-ischaemic areas of LGE. A previous study by Ntusi et al.32 found
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non-ischaemic LGE in 46% of 39 established RA patients. Focal fibrosis is generally considered a later
manifestation of disease, consistent with the lower rate of LGE in the CADERA study compared with this
previous study.
Treatment effects
The CADERA study has shown that aortic stiffness improves following treatment initiation in a treatment-
naive RA cohort. Although AD is a surrogate for risk, this finding underscores the importance of early
detection and treatment of CVD in patients with RA.
Furthermore, MECV as a marker of diffuse myocardial fibrosis improved from baseline to the 1-year
follow-up, suggesting that anti-inflammatory therapy can reverse some of the abnormal myocardial
findings associated with even early RA. These observations provide insights into the potential underlying
inflammatory (as well as fibrotic) mechanisms of myocardial fibrosis, which may offer novel therapeutic
opportunities for improving the outcomes of RA patients with co-existent CVD.
The type of treatment used had no statistically significant effect in the CADERA study: ETN as first-line
treatment was not superior to an initial csDMARD strategy in improving markers of CVD in the entire
study population. Unexpectedly, there was also no difference in AD change between responders and
non-responders from both treatment groups. To account for the dichotomous response measure ‘hiding’ a
disease activity effect an additional analysis of cumulative disease activity burden was undertaken, which
also indicated an absence of effect on AD change. Early TNFi bDMARD therapy appeared to provide
additional benefits in first-line bDMARD responders compared with csDMARD responders; however, the
difference was not statistically significant. If confirmed in larger studies, these data suggest that bDMARD
therapy with ETN may provide specific CVD benefits.
Lastly, we have demonstrated an increase in LVM following treatment for RA in both treatment arms.
Other markers of subclinical CVD, including LV strain indices, ECV and native myocardial T1 relaxation
time, did not improve significantly with treatment.
Study limitations
The sample size of this study was small for some of the secondary end points and larger studies will be
needed to test these end points with adequate power. Although we performed analyses to establish the
effect of age, sex, smoking and blood pressure between the control and patient groups, there may have
been other confounders that affected the comparisons. AD is related to CV risk but also varies with
age and normal values for AD are not clearly defined. Both treatment regimens were effective for the
treatment of RA, which translated into a comparable total burden of disease activity (and thus presumably
inflammation). This was by design and driven by the primary trial (VEDERA), which aimed to determine
whether or not initial ETN plus MTX offered greater benefit over an optimal initial csDMARD treat-to-target
strategy, with ‘optimal’ meaning efficient switching to ETN in those not achieving remission. A primary
cardiac-only study could have included continuation of csDMARD therapy in group 2 to create a greater
separation of disease burden, although this would be less clinically meaningful and would probably be
deemed unethical.
Conclusion
The CADERA study is the first randomised controlled trial to show changes in vascular function in
treatment-naive early RA of < 12 months’ symptom-duration patients compared with control subjects.
Optimal DMARD therapy (whether csDMARDs or bDMARDs) to control RA disease activity is associated
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with significant improvement in AD over a 48-week period. However, AD improvement over 48 weeks
appears not to be associated with response status per se (whether within a treatment arm strategy or not).
Exploratory evaluation suggests greater AD improvement with ETN/MTX compared with MTX (when
controlling for response status).
Recommendations
The CADERA study offers new insights into the relationship between RA disease activity (reflecting systemic
and local inflammation), subclinical CVD and the influence of RA-directed treatments. The presence of
vascular changes at the earliest stages of RA onset deserve validation to inform future evaluation of CVD
comorbidity. The ability to modify vascular and myocardial changes with RA therapy alone, with the
suggestion of drug-specific benefits, also warrants confirmation in larger studies.
Multicentre studies are thus needed, both for feasibility and for generalisability. Consistency in imaging
platforms, protocols and analysis approaches is crucial to deliver robust multicentre imaging studies.
Utilising research networks [such as National Institute for Health Research (NIHR) Biomedical Research
Centres and Clinical Research Facilities) and NIHR Translational Research Collaborations can foster such
interdisciplinary experimental studies.
DOI: 10.3310/eme08040 EFFICACY AND MECHANISM EVALUATION 2021 VOL. 8 NO. 4
© Queen’s Printer and Controller of HMSO 2021. This work was produced by Plein et al. under the terms of a commissioning contract issued by the Secretary of State for Health
and Social Care. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional
journals provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should
be addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science




This research was supported by the NIHR infrastructure at Leeds. The views expressed are those of theauthors and not necessarily those of the NHS, the NIHR or the Department of Health and Social Care.
Pfizer supported the parent study, VEDERA, through an investigator-sponsored research grant reference
WS1092499.
CADERA Trial Management Group
Sven Plein (CADERA principal investigator).
Maya H Buch (CADERA co-principal investigator).
Sue Pavitt (CADERA co-investigator).
Trial Steering Committee
Gerry Wilson (chairperson).
Sven Plein (CADERA principal investigator).
Maya H Buch (CADERA co-principal investigator).
Elizabeth Hensor (VEDERA statistician).
Bara Erhayiem (CADERA research fellow).
Graham Fent (CADERA research fellow).
Robert Storey (CADERA independent member).
Sue Watson (independent lay individual).
Anne-Maree Keenan (Biomedical Research Unit deputy director).
Sarah Horton (VEDERA research fellow).
David Pickles (VEDERA research nurse).
James Goulding (trial co-ordinator).
Sarah Fahy (trial co-ordinator).
Sue Smith (PPI manager).
Participants
Thank you to all trial patients for their essential contribution to the trial.
DOI: 10.3310/eme08040 EFFICACY AND MECHANISM EVALUATION 2021 VOL. 8 NO. 4
© Queen’s Printer and Controller of HMSO 2021. This work was produced by Plein et al. under the terms of a commissioning contract issued by the Secretary of State for Health
and Social Care. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional
journals provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should
be addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science
Park, Southampton SO16 7NS, UK.
23
Contributions of authors
Sven Plein (https://orcid.org/0000-0002-0997-4384) (Professor of Cardiology) conceived the CADERA
study. He also contributed to the writing of the report and had the opportunity to critically revise it.
Bara Erhayiem (https://orcid.org/0000-0002-9340-6127) was one of the principal clinical research
fellows (Cardiology) analysing the CMR imaging data. He also contributed to the writing of the report and
had the opportunity to critically revise it.
Graham Fent (https://orcid.org/0000-0003-3343-9872) was one of the principal clinical research fellows
(Cardiology) analysing the CMR imaging data. He also contributed to the writing of the report and had the
opportunity to critically revise it.
Jacqueline Andrews (https://orcid.org/0000-0001-8858-7149) contributed to the writing of the report
and had the opportunity to critically revise it.
John Greenwood (https://orcid.org/0000-0002-2861-0914) contributed to the writing of the report
and had the opportunity to critically revise it.
Paul Baxter (https://orcid.org/0000-0003-2699-3103) (Principal Statistician) worked with Elizabeth Hensor
to link the VEDERA and CADERA data and analyses appropriately and provided overall responsibility for the
statistics and research methodology. He also contributed to the writing of the report and had the opportunity
to critically revise it.
Elizabeth M Hensor (https://orcid.org/0000-0002-5245-4755) (Principal Statistician for the parent
VEDERA trial) worked with Paul Baxter to link the data and analyses appropriately and provided overall
responsibility for the statistics and research methodology. She also contributed to the writing of the report
and had the opportunity to critically revise it.
Sue Pavitt (https://orcid.org/0000-0001-7447-440X) (Professor in Translational and Applied Health
Research, Dentistry) conceived the CADERA study. She also contributed to the writing of the report and
had the opportunity to critically revise it.
Maya H Buch (https://orcid.org/0000-0002-8962-5642) (Professor of Rheumatology, Rheumatology)
conceived the CADERA study and provided overall responsibility for the statistics and research
methodology. She also contributed to the writing of the report and had the opportunity to critically
revise it.
Publications
Erhayiem B, McDiarmid A, Swoboda P, Kidambi A, Ripley D, Musa T, et al. Treatment-naive, early rheumatoid
arthritis patients demonstrate abnormalities of vascular and myocardial function on cardiac MRI. Arthritis
Rheumatol 2015;67(Suppl. 10).
Dumitru RB, Horton S, Hodgson R, Wakefield RJ, Hensor EMA, Emery P, Buch MH. A prospective,
single-centre, randomised study evaluating the clinical, imaging and immunological depth of remission
achieved by very early versus delayed Etanercept in patients with Rheumatoid Arthritis (VEDERA). BMC
Musculoskelet Disord 2016;17:61.
Plein S, Erhayiem B, Fent G, Horton S, Dumitru RB, Andrews J, et al. Cardiovascular effects of biological
versus conventional synthetic disease-modifying antirheumatic drug therapy in treatment-naïve, early
rheumatoid arthritis. Ann Rheum Dis 2020;79:1414–22.
ACKNOWLEDGEMENTS
NIHR Journals Library www.journalslibrary.nihr.ac.uk
24
Data-sharing statement
All data requests should be submitted to the corresponding author for consideration. Access to available
anonymised data may be granted following review.
Patient data
This work uses data provided by patients and collected by the NHS as part of their care and support. Using
patient data is vital to improve health and care for everyone. There is huge potential to make better use of
information from people’s patient records, to understand more about disease, develop new treatments,
monitor safety, and plan NHS services. Patient data should be kept safe and secure, to protect everyone’s
privacy, and it’s important that there are safeguards to make sure that it is stored and used responsibly.
Everyone should be able to find out about how patient data are used. #datasaveslives You can find out
more about the background to this citation here: https://understandingpatientdata.org.uk/data-citation.
DOI: 10.3310/eme08040 EFFICACY AND MECHANISM EVALUATION 2021 VOL. 8 NO. 4
© Queen’s Printer and Controller of HMSO 2021. This work was produced by Plein et al. under the terms of a commissioning contract issued by the Secretary of State for Health
and Social Care. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional
journals provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should
be addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science




1. Plein S, Erhayiem B, Fent G, Horton S, Dumitru RB, Andrews J, et al. Cardiovascular effects of biological
versus conventional synthetic disease-modifying antirheumatic drug therapy in treatment-naïve,
early rheumatoid arthritis. Ann Rheum Dis 2020;79:1414–22. https:/doi.org/10.1136/annrheumdis-
2020-217653
2. van Halm VP, Peters MJ, Voskuyl AE, Boers M, Lems WF, Visser M, et al. Rheumatoid arthritis
versus diabetes as a risk factor for cardiovascular disease: a cross-sectional study, the CARRE
Investigation. Ann Rheum Dis 2009;68:1395–400. https://doi.org/10.1136/ard.2008.094151
3. Peters MJ, van Halm VP, Voskuyl AE, Smulders YM, Boers M, Lems WF, et al. Does rheumatoid
arthritis equal diabetes mellitus as an independent risk factor for cardiovascular disease? A
prospective study. Arthritis Rheum 2009;61:1571–9. https://doi.org/10.1002/art.24836
4. del Rincón ID, Williams K, Stern MP, Freeman GL, Escalante A. High incidence of cardiovascular events
in a rheumatoid arthritis cohort not explained by traditional cardiac risk factors. Arthritis Rheum
2001;44:2737–45.
5. del Rincón I, Polak JF, O’Leary DH, Battafarano DF, Erikson JM, Restrepo JF, et al. Systemic
inflammation and cardiovascular risk factors predict rapid progression of atherosclerosis in
rheumatoid arthritis. Ann Rheum Dis 2015;74:1118–23. https://doi.org/10.1136/annrheumdis-
2013-205058
6. Maradit-Kremers H, Nicola PJ, Crowson CS, Ballman KV, Gabriel SE. Cardiovascular death in
rheumatoid arthritis: a population-based study. Arthritis Rheum 2005;52:722–32. https://doi.org/
10.1002/art.20878
7. Peters MJ, Symmons DP, McCarey D, Dijkmans BA, Nicola P, Kvien TK, et al. EULAR evidence-
based recommendations for cardiovascular risk management in patients with rheumatoid arthritis
and other forms of inflammatory arthritis. Ann Rheum Dis 2010;69:325–31. https://doi.org/
10.1136/ard.2009.113696
8. Agca R, Heslinga SC, Rollefstad S, Heslinga M, McInnes IB, Peters MJ, et al. EULAR
recommendations for cardiovascular disease risk management in patients with rheumatoid
arthritis and other forms of inflammatory joint disorders: 2015/2016 update. Ann Rheum Dis
2017;76:17–28. https://doi.org/10.1136/annrheumdis-2016-209775
9. Kerola AM, Kerola T, Kauppi MJ, Kautiainen H, Virta LJ, Puolakka K, Nieminen TV. Cardiovascular
comorbidities antedating the diagnosis of rheumatoid arthritis. Ann Rheum Dis 2013;72:1826–9.
https://doi.org/10.1136/annrheumdis-2012-202398
10. Kerola AM, Kauppi MJ, Kerola T, Nieminen TV. How early in the course of rheumatoid arthritis
does the excess cardiovascular risk appear? Ann Rheum Dis 2012;71:1606–15.
11. Aviña-Zubieta JA, Choi HK, Sadatsafavi M, Etminan M, Esdaile JM, Lacaille D. Risk of cardiovascular
mortality in patients with rheumatoid arthritis: a meta-analysis of observational studies. Arthritis
Rheum 2008;59:1690–7. https://doi.org/10.1002/art.24092
12. Barra LJ, Pope JE, Hitchon C, Boire G, Schieir O, Lin D, et al. The effect of rheumatoid arthritis-
associated autoantibodies on the incidence of cardiovascular events in a large inception cohort
of early inflammatory arthritis. Rheumatology 2017;56:768–76. https://doi.org/10.1093/
rheumatology/kew474
13. Solomon DH, Reed GW, Kremer JM, Curtis JR, Farkouh ME, Harrold LR, et al. Disease activity in
rheumatoid arthritis and the risk of cardiovascular events. Arthritis Rheumatol 2015;67:1449–55.
https://doi.org/10.1002/art.39098
DOI: 10.3310/eme08040 EFFICACY AND MECHANISM EVALUATION 2021 VOL. 8 NO. 4
© Queen’s Printer and Controller of HMSO 2021. This work was produced by Plein et al. under the terms of a commissioning contract issued by the Secretary of State for Health
and Social Care. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional
journals provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should
be addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science
Park, Southampton SO16 7NS, UK.
27
14. Smolen JS, Landewé R, Bijlsma J, Burmester G, Chatzidionysiou K, Dougados M, et al. EULAR
recommendations for the management of rheumatoid arthritis with synthetic and biological
disease-modifying antirheumatic drugs: 2016 update. Ann Rheum Dis 2017;76:960–77.
https://doi.org/10.1136/annrheumdis-2016-210715
15. Smolen JS, Aletaha D, Bijlsma JW, Breedveld FC, Boumpas D, Burmester G, et al. Treating
rheumatoid arthritis to target: recommendations of an international task force. Ann Rheum Dis
2010;69:631–7. https://doi.org/10.1136/ard.2009.123919
16. Kavanaugh A, Fleischmann RM, Emery P, Kupper H, Redden L, Guerette B, et al. Clinical,
functional and radiographic consequences of achieving stable low disease activity and remission
with adalimumab plus methotrexate or methotrexate alone in early rheumatoid arthritis: 26-week
results from the randomised, controlled OPTIMA study. Ann Rheum Dis 2013;72:64–71.
https://doi.org/10.1136/annrheumdis-2011-201247
17. Emery P, Hammoudeh M, FitzGerald O, Combe B, Martin-Mola E, Buch MH, et al. Sustained
remission with etanercept tapering in early rheumatoid arthritis. N Engl J Med 2014;371:1781–92.
https://doi.org/10.1056/NEJMoa1316133
18. Goekoop-Ruiterman YP, de Vries-Bouwstra JK, Allaart CF, van Zeben D, Kerstens PJ, Hazes JM, et al.
Clinical and radiographic outcomes of four different treatment strategies in patients with early
rheumatoid arthritis (the BeSt study): a randomized, controlled trial. Arthritis Rheum 2005;52:3381–90.
https://doi.org/10.1002/art.21405
19. Dixon WG, Watson KD, Lunt M, Hyrich KL, Silman AJ, Symmons DP, British Society for
Rheumatology Biologics Register Control Centre Consortium. Reduction in the incidence of
myocardial infarction in patients with rheumatoid arthritis who respond to anti-tumor necrosis
factor alpha therapy: results from the British Society for Rheumatology Biologics Register. Arthritis
Rheum 2007;56:2905–12. https://doi.org/10.1002/art.22809
20. Low AS, Symmons DP, Lunt M, Mercer LK, Gale CP, Watson KD, et al. Relationship between
exposure to tumour necrosis factor inhibitor therapy and incidence and severity of myocardial
infarction in patients with rheumatoid arthritis. Ann Rheum Dis 2017;76:654–60. https://doi.org/
10.1136/annrheumdis-2016-209784
21. Roubille C, Richer V, Starnino T, McCourt C, McFarlane A, Fleming P, et al. The effects of tumour
necrosis factor inhibitors, methotrexate, non-steroidal anti-inflammatory drugs and corticosteroids
on cardiovascular events in rheumatoid arthritis, psoriasis and psoriatic arthritis: a systematic review
and meta-analysis. Ann Rheum Dis 2015;74:480–9. https://doi.org/10.1136/annrheumdis-2014-
206624
22. Barnabe C, Martin BJ, Ghali WA. Systematic review and meta-analysis: anti-tumor necrosis factor
α therapy and cardiovascular events in rheumatoid arthritis. Arthritis Care Res 2011;63:522–9.
https://doi.org/10.1002/acr.20371
23. Dumitru RB, Horton S, Hodgson R, Wakefield RJ, Hensor EMA, Emery P, Buch MH. A prospective,
single-centre, randomised study evaluating the clinical, imaging and immunological depth of
remission achieved by very early versus delayed Etanercept in patients with Rheumatoid Arthritis
(VEDERA). BMC Musculoskelet Disord 2016;17:61. https://doi.org/10.1186/s12891-016-0915-0
24. Erhayiem B, Pavitt S, Baxter P, Andrews J, Greenwood JP, Buch MH, Plein S. Coronary Artery
Disease Evaluation in Rheumatoid Arthritis (CADERA): study protocol for a randomized controlled
trial. Trials 2014;15:436. https://doi.org/10.1186/1745-6215-15-436
25. Redheuil A, Wu CO, Kachenoura N, Ohyama Y, Yan RT, Bertoni AG, et al. Proximal aortic
distensibility Is an independent predictor of all-cause mortality and incident CV events: the MESA
study. J Am Coll Cardiol 2014;64:2619–29. https://doi.org/10.1016/j.jacc.2014.09.060
REFERENCES
NIHR Journals Library www.journalslibrary.nihr.ac.uk
28
26. Smolen JS, Breedveld FC, Burmester GR, Bykerk V, Dougados M, Emery P, et al. Treating rheumatoid
arthritis to target: 2014 update of the recommendations of an international task force. Ann Rheum
Dis 2016;75:3–15.
27. Aletaha D, Neogi T, Silman AJ, Funovits J, Felson DT, Bingham CO, et al. 2010 rheumatoid arthritis
classification criteria: an American College of Rheumatology/European League Against Rheumatism
collaborative initiative. Ann Rheum Dis 2010;69:1580–8. https://doi.org/10.1136/ard.2010.138461
28. Erhayiem B, McDiarmid A, Swoboda P, Kidambi A, Ripley D, Musa T, et al. Treatment-naive, early
rheumatoid arthritis patients demonstrate abnormalities of vascular and myocardial function on
cardiac MRI. Arthritis Rheumatol 2015;67(Suppl. 10).
29. Fransen J, Stucki G, van Riel PLCM. Rheumatoid arthritis measures. Disease Activity Score (DAS),
Disease Activity Score-28 (DAS28), Rapid Assessment of Disease Activity in Rheumatology (RADAR),
and Rheumatoid Arthritis Disease Activity Index (RADAI) Arthritis & Rheumatism 2003;49:S214–24.
https://doi.org/10.1002/art.11407
30. Ikdahl E, Rollefstad S, Wibetoe G, Olsen IC, Berg IJ, Hisdal J, et al. Predictive value of arterial
stiffness and subclinical carotid atherosclerosis for cardiovascular disease in patients with
rheumatoid arthritis. J Rheumatol 2016;43:1622–30. https://doi.org/10.3899/jrheum.160053
31. Giles JT, Malayeri AA, Fernandes V, Post W, Blumenthal RS, Bluemke D, et al. Left ventricular
structure and function in patients with rheumatoid arthritis, as assessed by cardiac magnetic
resonance imaging. Arthritis Rheum 2010;62:940–51. https://doi.org/10.1002/art.27349
32. Ntusi NAB, Piechnik SK, Francis JM, Ferreira VM, Matthews PM, Robson MD, et al. Diffuse
myocardial fibrosis and inflammation in rheumatoid arthritis: insights from CMR T1 mapping.
JACC Cardiovasc Imaging 2015;8:526–36. https://doi.org/10.1016/j.jcmg.2014.12.025
DOI: 10.3310/eme08040 EFFICACY AND MECHANISM EVALUATION 2021 VOL. 8 NO. 4
© Queen’s Printer and Controller of HMSO 2021. This work was produced by Plein et al. under the terms of a commissioning contract issued by the Secretary of State for Health
and Social Care. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional
journals provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should
be addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science
Park, Southampton SO16 7NS, UK.
29










Add SSZ + HCQ if LDA is not 
achieved










Stop ETN if applicable; continue treatment according
to NICE guidelines
FIGURE 2 Schematic of the trial design. HCQ, hydroxychloroquine; LDA, low disease activity; NICE, National Institute
for Health and Care Excellence; SSZ, sulfasalazine; TT, treat to target. Reproduced from Dumitru et al.23 This article is
distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.
org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you
give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and
indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.
org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
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Appendix 2 The CADERA study design
Parallel group
30 non-RA-matched controls
(age, BP risk factors)
The CADERA, a bolt-on study to the VEDERA trial
VERDERA trial (120 eligible participants)







in early RA receiving
biologic treatment
available to supplement
recruitment from the 





















1-year MRI – 45 patients analysed from
each trial arm
(primary end point stage 2)









Recruit 100 participants from VEDERA
and obtain baseline MRI
FIGURE 3 BP, blood pressure; MRI, magnetic resonance imaging, NIHR-LMBRU, National Institute for Health
Research – Biomedical Research Unit; TT, treat to target.
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Appendix 3 Additional tables






Ratio (95% CI); p-value
Unadjusted Adjusted 1b Adjusted 2c
Combined groups 1 and 2 (n = 81):
baseline, 1 year
60.3 (59.1 to 61.6),
59.9 (58.5 to 61.5)
1.0 (1.0 to 1.0);
0.54
N/A N/A
Group 1 at 1 year (all, n = 40) vs.
group 2 at 1 year (all, n = 41)
60.0 vs. 60.9 1.0 (1.0 to 1.1);
0.20
1.0 (1.0 to 1.1);
0.16
1.0 (1.0 to 1.1);
0.22
Combined groups 1 and 2 at 1 year
(non-responders, n = 38) vs. combined
groups 1 and 2 at 1 year (responders,
n = 43)
61.1 vs. 58.9 1.0 (0.9 to 1.0);
0.16
1.0 (0.9 to 1.0);
0.13
1.0 ( 0.9 to 1.0);
0.31
Group 1 at 1 year (non-responders,
n = 17) vs. group 1 at 1 year (responders,
n = 23)
59.7 vs. 58.4 1.0 (0.9 to 1.1);
0.54
1.0 (0.9 to 1.0);
0.24
1.0 (0.9 to 1.0);
0.38
Group 1 at 1 year (responders, n = 23)
vs. group 2a at 1 year (responders,
n = 13)
58.4 vs. 59.4 1.0 (0.9 to 1.1);
0.75
1.0 ( 1.0 to 1.1);
0.29
1.1 (1.0 to 1.2);
0.19
N/A, not applicable.
a Group 1: immediate ETN and MTX treatment; group 2: first-line MTX ± additional csDMARD therapy; group 2a: group 2
patients who continued csDMARD therapy and did not escalate to delayed ETN/MTX at week 24; non-responders:
patients with a DAS28-ESR of ≥ 2.6 at 48 weeks; responders: patients with DAS28-ESR of < 2.6 at 48 weeks.
b Adjusted 1: adjusted for baseline LVEF.
c Adjusted 2: adjusted for baseline AD, age, sex, systolic blood pressure and pack-years smoking (± baseline DAS28-ESR
as applicable).
Response assumed for patients whose responder status at 48 weeks was unknown.
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Ratio (95% CI); p-value
Unadjusted Adjusted 1b Adjusted 2c
Combined groups 1 and 2 (n = 81):
baseline, 2 years
60.3 (59.1 to 61.6),
60.1 (58.1 to 62.1)
1.0 (1.0 to 1.0);
0.82
N/A N/A
Group 1 at 1 year (all, n = 40) vs. group 2
at 1 year (all, n = 41)
59.3 vs. 60.9 1.0 (1.0 to 1.1);
0.44
1.0 (1.0 to 1.1);
0.46
1.0 (1.0 to 1.1);
0.41
Combined groups 1 and 2 at 1 year
(non-responders, n = 38) vs. combined
groups 1 and 2 at 1 year (responders,
n = 43)
61.2 vs. 59.2 1.0 (0.9 to 1.0);
0.31
1.0 (0.9 to 1.0);
0.33
1.0 (0.9 to 1.1);
0.54
Group 1 at 1 year (non-responders,
n = 17) vs. group 1 at 1 year (responders,
n = 23)
60.6 vs. 58.4 1.0 (0.9 to 1.1);
0.46
1.0 (0.9 to 1.1);
0.32
1.0 ( 0.9 to 1.1);
0.41
Group 1 at 1 year (responders, n = 23) vs.
group 2a at 1 year (responders, n = 13)
58.4 vs. 59.8 1.0 (0.9 to 1.2);
0.67
1.0 (0.9 to 1.2);
0.57
1.1 (0.9 to 1.2);
0.45
N/A, not applicable.
a Group 1: immediate ETN and MTX treatment; group 2: first-line MTX ± additional csDMARD therapy; group 2a: group 2
patients who continued csDMARD therapy and did not escalate to delayed ETN/MTX at week 24; non-responders:
patients with a DAS28-ESR of ≥ 2.6 at 48 weeks; responders: patients with DAS28-ESR of < 2.6 at 48 weeks.
b Adjusted 1: adjusted for baseline LVEF.
c Adjusted 2: adjusted for baseline AD, age, sex, systolic blood pressure and pack-years smoking (± baseline DAS28-ESR
as applicable).
Response assumed for patients whose responder status at 48 weeks was unknown.






Ratio (95% CI); p-value
Unadjusted Adjusted 1b Adjusted 2c
Combined groups 1 and 2 (n = 81):
baseline, 1 year
1.1 (1.1 to 1.2),
1.1 (1.1 to 1.2)
1.0 (1.0 to 1.1);
0.84
N/A N/A
Group 1 at 1 year (all, n = 40) vs. group 2
at 1 year (all, n = 41)
1.2 vs. 1.1 1.0 (0.9 to 1.1);
0.33
0.9 (0.9 to 1.0);
0.21
0.9 (0.9 to 1.0);
0.21
Combined groups 1 and 2 at 1 year
(non-responders, n = 38) vs. combined
groups 1 and 2 at 1 year (responders,
n = 43)
1.1 vs. 1.2 1.1 (1.0 to 1.2);
0.30
1.1 (1.0 to 1.2);
0.29
1.1 (0.9 to 1.2);
0.38
Group 1 at 1 year (non-responders,
n = 17) vs. group 1 at 1 year (responders,
n = 23)
1.2 vs. 1.2 1.0 (0.9 to 1.1);
0.83
1.0 (0.9 to 1.1);
0.92
1.0 (0.9 to 1.1);
0.98
Group 1 at 1 year (responders, n = 23) vs.
group 2a at 1 year (responders, n = 13)
1.2 vs. 1.2 1.0 (0.9 to 1.1);
0.81
1.0 (0.9 to 1.2);
0.97
1.0 (0.9 to 1.2);
0.96
N/A, not applicable.
a Group 1: immediate ETN and MTX treatment; group 2: first-line MTX ± additional csDMARD therapy; group 2a: group 2
patients who continued csDMARD therapy and did not escalate to delayed ETN/MTX at week 24; non-responders:
patients with a DAS28-ESR of ≥ 2.6 at 48 weeks; responders: patients with DAS28-ESR of < 2.6 at 48 weeks.
b Adjusted 1: adjusted for baseline LVLS.
c Adjusted 2: adjusted for baseline AD, age, sex, systolic blood pressure and pack-years smoking (± baseline DAS28-ESR
as applicable).
Response assumed for patients whose responder status at 48 weeks was unknown.
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Ratio (95% CI); p-value
Unadjusted Adjusted 1b Adjusted 2c
Combined groups 1 and 2 (n = 81):
baseline, 2 years
1.1 (1.1 to 1.2),
1.0 (0.9 to 1.2)
0.9 (0.8 to 1.1);
0.27
N/A N/A
Group 1 at 1 year (all, n = 40) vs. group 2
at 1 year (all, n = 41)
1.0 vs. 1.1 1.0 (0.8 to 1.3);
0.77
1.0 (0.8 to 1.3);
0.75
1.0 (0.8 to 1.3);
0.80
Combined groups 1 and 2 at 1 year
(non-responders, n = 38) vs. combined
groups 1 and 2 at 1 year (responders,
n = 43)
1.0 vs. 1.1 1.0( 0.8 to 1.3);
0.91
1.0 (0.8 to 1.3);
0.91
1.0 (0.8 to 1.3);
0.75
Group 1 at 1 year (non-responders,
n = 17) vs. group 1 at 1 year (responders,
n = 23)
1.0 vs. 1.1 1.1 (0.8 to 1.6);
0.57
1.1 (0.8 to 1.7);
0.55
1.1 (0.7 to 1.7);
0.56
Group 1 at 1 year (responders, n = 23) vs.
group 2a at 1 year (responders, n = 13)
1.1 vs. 1.0 1.0( 0.7 to 1.4);
0.87
1.0 (0.7 to 1.4);
0.85
1.0 (0.6 to 1.6);
0.97
N/A, not applicable.
a Group 1: immediate ETN and MTX treatment; group 2: first-line MTX ± additional csDMARD therapy; group 2a: group 2
patients who continued csDMARD therapy and did not escalate to delayed ETN/MTX at week 24; non-responders:
patients with a DAS28-ESR of ≥ 2.6 at 48 weeks; responders: patients with DAS28-ESR of < 2.6 at 48 weeks.
b Adjusted 1: adjusted for baseline LVLS.
c Adjusted 2: adjusted for baseline AD, age, sex, systolic blood pressure and pack-years smoking (± baseline DAS28-ESR
as applicable).
Response assumed for patients whose responder status at 48 weeks was unknown.






Ratio (95% CI); p-value
Unadjusted Adjusted 1b Adjusted 2c
Combined groups 1 and 2 (n = 81):
baseline, 1 year
14.9 (13.9 to 15.8),
14.6 (13.7 to 15.7)
1.0 (0.9 to 1.1);
0.69
N/A N/A
Group 1 at 1 year (all, n = 40) vs. group 2
at 1 year (all, n = 41)
14.5 vs. 14.8 1.0 (0.9 to 1.2);
0.75
1.0 (0.9 to 1.2);
0.80
1.0 (0.9 to 1.2);
0.96
Combined groups 1 and 2 at 1 year
(non-responders, n = 38) vs. combined
groups 1 and 2 at 1 year (responders,
n = 43)




1.0 (0.8 to 1.1);
0.61
Group 1 at 1 year (non-responders,
n = 17) vs. group 1 at 1 year (responders,
n = 23)
15.0 vs. 14.1 1.0 (0.8 to 1.2);
0.58
0.9 (0.8 to 1.1);
0.50
1.0 (0.8 to 1.2);
0.60
Group 1 at 1 year (responders, n = 23) vs.
group 2a at 1 year (responders, n = 13)
14.1 vs. 15.4 1.1 (0.9 to 1.4);
0.49
1.1 (0.9 to 1.4);
0.44
1.1 (0.8 to 1.4);
0.75
N/A, not applicable.
a Group 1: immediate ETN and MTX treatment; group 2: first-line MTX ± additional csDMARD therapy; group 2a: group 2
patients who continued csDMARD therapy and did not escalate to delayed ETN/MTX at week 24; non-responders:
patients with a DAS28-ESR of ≥ 2.6 at 48 weeks; responders: patients with DAS28-ESR of < 2.6 at 48 weeks.
b Adjusted 1: adjusted for baseline PLVTw.
c Adjusted 2: adjusted for baseline AD, age, sex, systolic blood pressure and pack-years smoking (± baseline DAS28-ESR
as applicable).
Response assumed for patients whose responder status at 48 weeks was unknown.
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Ratio (95% CI); p-value
Unadjusted Adjusted 1b Adjusted 2c
Combined groups 1 and 2 (n = 81):
baseline, 2 years
14.9 (14.0 to 15.9),
16.6 (15.5 to 17.8)
1.1 (1.0 to 1.2);
0.02
N/A N/A
Group 1 at 1 year (all, n = 40) vs. group 2
at 1 year (all, n = 41)
16.7 vs. 16.4 1.0 (0.9 to 1.1);
0.78
1.0 (0.9 to 1.1);
0.76
1.0 (0.9 to 1.2);
0.75
Combined groups 1 and 2 at 1 year
(non-responders, n = 38) vs. combined
groups 1 and 2 at 1 year (responders,
n = 43)
16.5 vs. 16.6 1.0 (0.8 to 1.2);
0.95
1.0 (0.8 to 1.2);
1.00
1.1 (0.9 to 1.3);
0.64
Group 1 at 1 year (non-responders,
n = 17) vs. group 1 at 1 year (responders,
n = 23)
16.6 vs. 17.6 1.1 (0.8 to 1.4);
0.61
1.1 (0.8 to 1.4);
0.60
1.1 (0.8 to 1.5);
0.44
Group 1 at 1 year (responders, n = 23) vs.
group 2a at 1 year (responders, n = 13)
16.7 vs. 16.4 1.0 (0.9 to 1.1);
0.78
1.0 (0.9 to 1.1);
0.76
1.0 (0.9 to 1.2);
0.75
N/A, not applicable.
a Group 1: immediate ETN and MTX treatment; group 2: first-line MTX ± additional csDMARD therapy; group 2a: group 2
patients who continued csDMARD therapy and did not escalate to delayed ETN/MTX at week 24; non-responders:
patients with a DAS28-ESR of ≥ 2.6 at 48 weeks; responders: patients with DAS28-ESR of < 2.6 at 48 weeks.
b Adjusted 1: adjusted for baseline PLVTw.
c Adjusted 2: adjusted for baseline AD, age, sex, systolic blood pressure and pack-years smoking (± baseline DAS28-ESR
as applicable).
Response assumed for patients whose responder status at 48 weeks was unknown.






Ratio (95% CI); p-value
Unadjusted Adjusted 1b Adjusted 2c
Combined groups 1 and 2 (n = 81):
baseline, 1 year
78.2 (73.7 to 82.9),
81.4 (76.3 to 86.9)
1.0 (1.0 to 1.1);
0.01
N/A N/A
Group 1 at 1 year (all, n = 40) vs. group 2
at 1 year (all, n = 41)
80.9 vs. 81.9 1.0 (0.9 to 1.2);
0.84
1.0 (1.0 to 1.1);
0.68
1.0 (1.0 to 1.1);
0.35
Combined groups 1 and 2 at 1 year
(non-responders, n = 38) vs. combined
groups 1 and 2 at 1 year (responders,
n = 43)
76.0 vs. 86.5 1.1 (1.0 to 1.3);
0.05
1.0 (0.9 to 1.1);
0.88
1.0 (0.9 to 1.1);
0.69
Group 1 at 1 year (non-responders,
n = 17) vs. group 1 at 1 year (responders,
n = 23)
76.9 vs. 83.9 1.1 (0.9 to 1.3);
0.33
1.0 (0.9 to 1.1);
0.80
1.0 (0.9 to 1.1);
0.65
Group 1 at 1 year (responders, n = 23) vs.
group 2a at 1 year (responders, n = 13)
83.9 vs. 87.5 1.0 (0.8 to 1.3);
0.71
1.0 (0.9 to 1.1);
0.74
1.0 (0.9 to 1.2);
0.78
N/A, not applicable.
a Group 1: immediate ETN and MTX treatment; group 2: first-line MTX ± additional csDMARD therapy; group 2a: group 2
patients who continued csDMARD therapy and did not escalate to delayed ETN/MTX at week 24; non-responders:
patients with a DAS28-ESR of ≥ 2.6 at 48 weeks; responders: patients with DAS28-ESR of < 2.6 at 48 weeks.
b Adjusted 1: adjusted for baseline LVM.
c Adjusted 2: adjusted for baseline AD, age, sex, systolic blood pressure and pack-years smoking (± baseline DAS28-ESR
as applicable).
Response assumed for patients whose responder status at 48 weeks was unknown.
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Ratio (95% CI); p-value
Unadjusted Adjusted 1b Adjusted 2c
Combined groups 1 and 2 (n = 81):
baseline, 2 years
78.2 (73.7 to 82.9),
85.5 (79.0 to 92.6)
1.1 (1.0 to 1.2);
0.02
N/A N/A
Group 1 at 1 year (all, n = 40) vs. group 2
at 1 year (all, n = 41)
85.1 vs. 86.0 1.0 (0.9 to 1.2);
0.90
1.0 (0.9 to 1.2);
0.90
1.0 (0.9 to 1.2);
0.78
Combined groups 1 and 2 at 1 year
(non-responders, n = 38) vs. combined
groups 1 and 2 at 1 year (responders,
n = 43)
80.5 vs. 90.2 1.1 (1.0 to 1.3);
0.17
1.0 (0.9 to 1.2);
0.60
1.0 (0.9 to 1.2);
0.83
Group 1 at 1 year (non-responders,
n = 17) vs. group 1 at 1 year (responders,
n = 23)
80.8 vs. 88.4 1.1 (0.9 to 1.4);
0.43
1.0 (0.8 to 1.3);
0.79
1.0 (0.8 to 1.3);
0.98
Group 1 at 1 year (responders, n = 23) vs.
group 2a at 1 year (responders, n = 13)
88.4 vs. 90.0 1.0 (0.8 to 1.3);
0.90
1.0 (0.8 to 1.3);
0.86
1.0 (0.8 to 1.4);
0.83
N/A, not applicable.
a Group 1: immediate ETN and MTX treatment; group 2: first-line MTX ± additional csDMARD therapy; group 2a: group 2
patients who continued csDMARD therapy and did not escalate to delayed ETN/MTX at week 24; non-responders:
patients with a DAS28-ESR of ≥ 2.6 at 48 weeks; responders: patients with DAS28-ESR of < 2.6 at 48 weeks.
b Adjusted 1: adjusted for baseline LVM.
c Adjusted 2: adjusted for baseline AD, age, sex, systolic blood pressure and pack-years smoking (± baseline DAS28-ESR
as applicable).
Response assumed for patients whose responder status at 48 weeks was unknown.






Ratio (95% CI); p-value
Unadjusted Adjusted 1b Adjusted 2c
Combined groups 1 and 2 (n = 81):
baseline, 1 year
27.2 (26.4 to 28.1),
26.4 (25.6 to 27.1)
1.0 (0.9 to 1.0);
0.06
N/A N/A
Group 1 at 1 year (all, n = 40) vs. group 2
at 1 year (all, n = 41)
26.2 vs. 26.5 1.0 (1.0 to 1.1);
0.69
1.0 (1.0 to 1.1);
0.68
1.0 (0.9 to 1.1);
0.88
Combined groups 1 and 2 at 1 year
(non-responders, n = 38) vs. combined
groups 1 and 2 at 1 year (responders,
n = 43)
26.4 vs. 26.3 1.0 (0.9 to 1.1);
0.90
1.0 (0.9 to 1.1);
0.81
1.0 (1.0 to 1.1);
0.72
Group 1 at 1 year (non-responders,
n = 17) vs. group 1 at 1 year (responders,
n = 23)
25.9 vs. 26.5 1.0 (0.9 to 1.1);
0.61
1.0 (0.9 to 1.1);
0.87
1.0 (0.9 to 1.1);
0.46
Group 1 at 1 year (responders, n = 23) vs.
group 2a at 1 year (responders, n = 13)
26.5 vs. 26.6 1.0 (0.9 to 1.1);
0.91
1.0 (0.9 to 1.1);
0.56
1.0 (0.9 to 1.1);
0.68
N/A, not applicable.
a Group 1: immediate ETN and MTX treatment; group 2: first-line MTX ± additional csDMARD therapy; group 2a: group 2
patients who continued csDMARD therapy and did not escalate to delayed ETN/MTX at week 24; non-responders:
patients with a DAS28-ESR of ≥ 2.6 at 48 weeks; responders: patients with DAS28-ESR of < 2.6 at 48 weeks.
b Adjusted 1: adjusted for baseline MECV.
c Adjusted 2: adjusted for baseline AD, age, sex, systolic blood pressure and pack-years smoking (± baseline DAS28-ESR
as applicable).
Response assumed for patients whose responder status at 48 weeks was unknown.
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Ratio (95% CI); p-value
Unadjusted Adjusted 1b Adjusted 2c
Combined groups 1 and 2 (n = 81):
baseline, 2 years
27.2 (26.4 to 28.0),
27.0 (25.5 to 28.6)
1.0 (0.9 to 1.1);
0.77
N/A N/A
Group 1 at 2 years (all, n = 40) vs. group
2 at 2 years (all, n = 41)
26.6 vs. 27.3 1.0 (0.9 to 1.1);
0.60
1.0 (0.9 to 1.1);
0.60
1.0 (0.9 to 1.1);
0.67
Combined groups 1 and 2 at 2 years
(non-responders, n = 38) vs. combined
groups 1 and 2 at 2 years (responders,
n = 43)
26.4 vs. 27.5 1.0 (1.0 to 1.1);
0.38
1.0 (1.0 to 1.1);
0.39
1.1 (1.0 to 1.2);
0.17
Group 1 at 2 years (non-responders,
n = 17) vs. group 1 at 2 years
(responders, n = 23)
25.9 vs. 27.2 1.1 (0.9 to 1.2);
0.43
1.0 (0.9 to 1.2);
0.55
1.1 (0.9 to 1.3);
0.29
Group 1 at 2 years (responders, n = 23)
vs. group 2a at 2 years (responders,
n = 13)
27.2 vs. 27.5 1.0 (0.9 to 1.2);
0.86
1.0 (0.9 to 1.2);
0.73
1.0 (0.8 to 1.2);
0.96
N/A, not applicable.
a Group 1: immediate ETN and MTX treatment; group 2: first-line MTX ± additional csDMARD therapy; group 2a: group 2
patients who continued csDMARD therapy and did not escalate to delayed ETN/MTX at week 24; non-responders:
patients with a DAS28-ESR of ≥ 2.6 at 48 weeks; responders: patients with DAS28-ESR of < 2.6 at 48 weeks.
b Adjusted 1: adjusted for baseline MECV.
c Adjusted 2: adjusted for baseline AD, age, sex, systolic blood pressure and pack-years smoking (± baseline DAS28-ESR
as applicable).
Response assumed for patients whose responder status at 48 weeks was unknown.







































Age (years) 23 (45, 15.5) 17 (49, 12) 20 (51, 23.5) 21 (54, 19) 13 (59, 19) 6 (46, 26.5)















23 (121, 27.5) 17 (124, 22) 20 (118, 18.7) 21 (121, 24) 13 (122, 16) 6 (125.5, 11)
Pack-years
smoking
23 (0, 4.8) 17 (0, 6) 20 (0, 20) 21 (5 14.3) 13 (0, 24) 6 (2.6, 6.2)
a Group 1: immediate ETN and MTX treatment; group 2: first-line MTX ± additional csDMARD therapy; group 2a: group 2
patients who continued csDMARD therapy and did not escalate to delayed ETN/MTX at week 24; non-responders:
patients with a DAS28-ESR of ≥ 2.6 at 48 weeks; responders: patients with DAS28-ESR of < 2.6 at 48 weeks.
Response assumed for patients whose responder status at 48 weeks was unknown
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Appendix 4 Protocol amendments July 2018
For analysis of primary, secondary and exploratory outcomes in CADERA patients at 1-year and 2-yearfollow-up, an ANCOVA method has been adopted. The outcome at follow-up is linearly regressed
on a grouping variable (defined below) as dependent variable, first as an unadjusted analysis (exploring
differences by group in the outcome at 1 year or 2 years), second additionally adjusted for baseline
outcome (an ANCOVA approach to analysis of change, replacing the differences to baseline method
originally proposed) and, third, additionally adjusted for baseline outcome, age, sex, systolic blood pressure
and, where appropriate (see below), baseline DAS28-ESR (again, an ANCOVA approach to analysis of
change, replacing the differences from baseline method originally proposed). The change of approach
from differences to baseline to ANCOVA was undertaken for consistency with the preliminary analysis
presented to the Efficacy and Mechanism Evaluation programme in 2017 and to enhance power given
the additional grouped analyses to be undertaken (see below). Outcomes are naturally log transformed to
achieve normality assumptions. Back-transformation is performed when presenting results, thus estimates
are geometric means or ratios across groups.
Groups were defined as follows where group 1 are patients on first-line ETN/MTX and group 2 are patients
on first-line ETN/MTX with possible escalation at week 24.
Group 1 (all patients) versus group 2 (all patients).
Combined group 1 and group 2 (responders) versus combined group 1 and group 2 (non-responders)
adjusting for baseline DAS28-ESR.
Group 1 (responders) and group 1 (non-responders) adjusting for baseline DAS28-ESR
Group 1 (responders) and group 2a (responders) adjusting for baseline DAS28-ESR.
Patients with a DAS28-ESR of ≥ 2.6 at 48 weeks considered non-responders. Patients with missing
DAS28-ESR at week 48 for reasons other than withdrawal for lack of efficacy were assumed to be
responders in the initial analysis. The data were then reanalysed assuming they were non-responders.
For an intention-to-treat analysis, multiple imputation by chained equations was used to create 50 complete
data sets per outcome analysed. The results from which were combined according to Rubin’s rules. The
imputation model included the following variables at weeks 0, 12, 24, 36 and 48: SJC44, RAI, CRP, ESR,
physician VAS, patient general health VAS, patient pain VAS, patient disease activity VAS and early morning
stiffness. Outcome values at 1 or 2 years were included (dependent on outcome analysed) in addition to
baseline values. The model also included age, sex, systolic blood pressure, symptom duration, treatment
and an indicator for whether or not the patient was a responder (as defined above). Multiple imputation
chain mixing and distribution diagnostics were checked for plausibility of imputations.
For the primary outcome (AD) at 1 year only, an analysis adjusted for AUC disease activity is reported. A trapezoid
rule is used based on DAS28-ESR at weeks 0, 12, 24, 36 and 48 to calculate AUC. The imputation model
for this analysis excluded the indicator variable for whether or not a patient was a responder.
Amendments to analysis plan following reviewer comments.
The first 30 CADERA patients (cases) were approximately matched by age and sex to volunteers (control
subjects) who were invited for a cardiac scan and matched pairs analysis conducted on the primary outcome
(AD), secondary outcomes (LVEF, LVLS, PLVTw and left ventricular mass) and the exploratory outcome (MECV)
at baseline. Three patients from these 30 were excluded due to screen failure for the VADERA study, thus a
maximum of 27 matched pairs were available for analysis. To reflect the approximate matching, additional
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linear regression analyses are presented for each of the primary, secondary and exploratory outcomes at
baseline including the 30 control subjects and all cases where data are available. Each analysis is presented
unadjusted (with a single independent variable case/control) and adjusted (with dependent variables case/
control, age, sex, systolic blood pressure and pack-years smoked). Outcomes are natural log transformed to
achieve normality assumptions (an approach favoured over non-parametric analysis to allow straightforward
adjustment in the additional regression analyses and consistency with the analyses at 1-year and 2-year
follow-up as described under point 2 below). Back transformation is performed when presenting results
(thus, geometric mean ratios and associated 95% CIs are reported). To assess balance of demographic
characteristics across all cases and the 30 control subjects, summary statistics are presented including for
key demographics of age, sex, systolic blood pressure and pack-years smoked.
For comparison, key demographics are presented for those CADERA patients who have at least one
primary, secondary or exploratory outcome missing at 1-year and 2-year follow-up, versus CADERA
patients who have complete data for all outcomes at 1 year and 2 years.
For further comparison key demographics are presented for CADERA patients split by group 1, group 2,
group 2a responders and non-responders.
Pack-years smoked was added as a variable to the analysis of primary, secondary and exploratory
outcomes (as described in the protocol amendment 1 of July 2018).
APPENDIX 4
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